EDGAR 10-K Filing

Company CIK: 725394
Filing Year: 2025
Filename: 725394_10-K_2025_0001683168-25-000285.json

---

ITEM 1. BUSINESS
Item 1. Description of Business
Company Overview
Moving the world forward takes bold resolve that turns ideas into actions and builds real-time solutions that positively impact people and the planet. Dalrada Financial Corporation (“Dalrada” or the “Company”) accelerates positive change for current and future generations by harnessing true potential and developing products and services that become transformative innovations.
Dalrada was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTC: DFCO.
Dalrada has five business divisions: Genefic, Dalrada Climate Technology, Dalrada Precision Manufacturing, Dalrada Technologies and Dalrada Corporate. Within each of these divisions, the Company drives transformative innovation while creating solutions that are sustainable, accessible, and affordable. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.
Genefic
Genefic delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, When the world needs advanced health care, Genefic delivers with ingenuity, accessibility, and affordability. This specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity- on a global level.
Genefic Specialty Pharmacy (“Genefic Pharmacy”)- Genefic Pharmacy (formerly Genefic Specialty Pharmacy Rx Solutions) is an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Genefic Pharmacy specializes in providing expert care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions. Genefic Pharmacy maintains pharmacy licenses in all 50 States as well as Washington D.C.
Genefic Infusion Rx- Genefic Infusion Rx is a Louisiana-based infusion pharmacy which handles all aspects of fluid and medication infusion, via intravenous or subcutaneous application. Genefic Infusion Rx serves as an essential with healthcare systems, enhancing the infusion process through efficient authorization and prescription management. Its state-of-the-art compounding facility is led by one of only eight pharmacists in Louisiana with a sterile compounding board certification, ensuring top-tier precision and quality in medication preparation.
Boost Diagnostics- Boost Diagnostics (formerly Empower Genomics and Genefic Diagnostics) is Dalrada’s wholly owned diagnostic laboratory subsidiary which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Boost Diagnostics has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Boost Diagnostics also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.
Pala Diagnostics (“Pala”)- Pala was a joint venture diagnostic laboratory entity which processed both molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Pala was no longer an operational entity as of June 30, 2023.
Dalrada Career Institute (“DCI”) (aka International Health Group (“IHG”)) - IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility. DCI started its first RN, nursing class in February of 2024 and this first class will be completed in February 2025. It is the intent of DCI to double their class size when it begins its second class in 2025.
Dalrada Climate Technology (formerly Dalrada Energy Services)
Dalrada Climate Technology (“DCT”) is a segment which incapsulates energy services and state-of-the-art technology within the climate sustainability space. DCT employs next-generation technology and services which enhances clean energy efforts while reducing the world’s carbon footprint. As a premier industrial heat pump manufacturer, Dalrada delivers innovation and efficiency, building solutions that reduce energy consumption and minimize carbon footprints, increase operational efficiencies, meet environmental, social, and governance (ESG) goals, and lower energy costs for clients.
Dalrada Technology Limited (“DTL”) - DTL is a holding company for all United Kingdom and European based Dalrada Climate Technology entities.
Likido Ltd. (“Likido”) - Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. Likido’s products currently include the DCT One Heat Pumps (formerly Likido®ONE) and DCT Cryo Chiller. Likido also offers heat pump solutions specifically designed for residential purposes.
During the prior year, the U.S. Government selected DCT One Series high-performance, low-carbon heat pump for real-world testing in a prestigious clean energy program. The implementation of the DCT One Series testing is still in process. The expected positive results should not only increase market acceleration and adoption within the federal government acceptance of groundbreaking eco-friendly technology but should also accelerate adoption within the commercial building industry.
Dalrada Technology Spain L.T. (“DTS”)- DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing and sale of the DCT One Series and DCT Cryo Chiller throughout Europe.
Dalrada Energy Services (“DES”)- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity. DES helps organizations meet ESG goals and standards while mitigating negative environmental impacts.
Bothof Brothers Construction (“Bothof”)- Bothof is a licensed general contractor which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting, the DES division can provide a myriad of additional services to its private and public works customers.
Dalrada Home Corporation (“Dalrada Home”)- Dalrada Home Corporation was established in February of 2024. Dalrada Home’s cutting-edge sustainability solutions are designed specifically for residential purposes. Our home heat pumps help us lead the way in providing innovative climate technology products and services to residential customers.
Dalrada Precision Manufacturing
Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.
Dalrada Precision Parts (“Precision”) - Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.
Deposition Technologies (“DepTec”) - DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.
DepTec has built an impressive catalogue of precision OEM parts for PVD (Physical vapor deposition) systems and the Company’s refurbished systems which allows clients the option of purchasing the same model of system they’ve been using for decades -but with significant upgrades and improved efficiencies. Older systems can now operate more reliably with additional control and monitoring plus longer lifespans. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs.
Ignite I.T. (“Ignite”) - Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meets or exceed the most stringent industry-testing specifications.
Dalrada Technologies
Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.
Prakat (“Prakat”) - Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.
Dalrada Corporate
Dalrada Corporate covers the activities which support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal advice, information technology, and marketing. It also contains executive management and shareholder-related services.
Research and Development
We spent $0 and $120,000 on research and development activities during the years ended June 30, 2024, and 2023, respectively. We anticipate that we will incur additional expenses on research and development over the next 12 months. Our planned expenditures on our operations or a business combination are summarized under the section of this Annual Report on form 10-K entitled “Management’s Discussion and Analysis of Financial Position and Results of Operations”.

---

ITEM 1A. RISK FACTORS
Item 1A. Risk Factors
Not applicable to smaller reporting companies.

---

ITEM 1B. UNRESOLVED STAFF COMMENTS
Item 1B. Unresolved Staff Comments
Not applicable to smaller reporting companies.

---

ITEM 2. PROPERTIES
Item 2. Description of Property
We currently lease 110,838 square feet of office, medical, pharmacy and warehouse space in California, Alabama, Texas, Louisiana, Scotland, and India, with leases that expire through 2028.
Square
Footage
Lease
Location
Type
(approximate)
Expiration
Escondido, California
Corporate Headquarters
49,530
6/30/2027
San Diego, California
Office
8,228
3/14/2028
Escondido, California
Office
2,992
6/30/2027
Chula Vista, California
Office, Medical Suite
3,200
11/12/2024
San Diego, California
Office, Medical Suite
9,016
8/31/2028
Bengaluru, India
Office
3,300
4/1/2026
Coronado, California
Office, Medical Suite
12/31/2024
Florence, Alabama
Pharmacy
1,443
5/31/2025
Livingston, Scotland
Office, Warehouse
4,500
8/27/2025
Escondido, California
Office
12/31/2024
Livingston, Scotland
Office, Warehouse
19,000
11/2/2027
Bergondo, Spain
Office, Warehouse
9,000
5/31/2028
Metairie, Louisiana
Office, Medical Suite
6,468
9/30/2025

---

ITEM 3. LEGAL PROCEEDINGS
Item 3. Legal Proceedings
Genefic Products (“Dalrada Health”), a subsidiary of Dalrada Financial Corporation, formed a joint venture with Vivera Pharmaceuticals, Inc. (“Vivera”), whereby Vivera is the minority member. As the managing member of the joint venture, Genefic Products, in December 2021, filed suit against Vivera and Paul Edalat, Vivera’s Chairman and CEO, for misappropriation of funds on behalf of the joint venture in the amount of $2,104,509. In addition to filing a cross-complaint against Genefic Products, Vivera filed a separate complaint against Dalrada Financial Corporation, Empower Genomics (a subsidiary of Dalrada Financial Corporation), Dalrada Financial Corporation’s officers, and other unrelated parties. The proceedings are being held at the Superior Court of the State of California, for the County of Orange - Central Justice Center.
In September 2023, Kroger Specialty Pharmacy LLC (“Kroger”) filed lawsuits/preliminary injunctions against Genefic Specialty Pharmacy and two of its employees who were former employees of Kroger. The lawsuits were filed in Tennessee and Alabama, respectively. The basis for the injunction arose from a non-compete clause in the contract between the two employees and a company which was later acquired by Kroger. In April 2024, the Court in the Tennessee case granted the preliminary injunction on the Tennessee employee, which is due to expire in April 2025. The case against the Tennessee employee is under appeal. No injunction has yet been issued against the Alabama employee.
In September 2023, Asset Group, Inc. (“Asset”) filed a breach of contract with Dalrada Health Products (“DHP”) in the Superior Court of San Diego. The case arises out of a Purchase Order wherein Asset agreed to pay DHP the sum of $3,240,000 for the purchase of 1,800,000 IRIS Ear Loop Face Masks during the COVID-19 pandemic. Asset filed a complaint alleging DHP did not have authority to sell the masks. However, DHP have provided their counsel with proof of authority and are preparing a Cross-Complaint for Asset’s material breach of the contract. This matter is currently set for trial January 31, 2025.
In March 2024, MDIQ filed a breach of contract with Dalrada Financial Corporation (“DFCO”) in Collin County Texas Superior Court. MDIQ was hired to process insurance claims for COVID-19 testing performed by Empower Genomics. MDIQ failed to perform yet filed a civil collection case against DFCO for failure to pay the invoices. DFCO is now in the process of counter suing for approximately $2,000,000 of unpaid claims that we would have benefitted from had MDIQ performed according to the contract.
A former consultant, Simon Gray, and distribution representative, DePrey Company, acted in concert with supplier Zhongshan Mide Hardware Products Co., Ltd. (“Mide”) to steal Fastenal Company purchase orders and effectively try to cut Dalrada Manufacturing out of its contractual relationship. DFCO has filed a lawsuit against DePrey Company and Simon Gray in July for a breach of contract and intentional interference with contractual relationships in the California Southern District Court.
In June 2024, Dalrada Financial Corporation (“DFCO”) filed a case in the California Southern District Court alleging, among other causes of action, fraud, breach of contract, unjust enrichment following DFCO purchasing Likido company from Stuart Cox and his failure to disclose pertinent financial liabilities he had incurred prior to the sale of the company to DFCO. Mr. Cox resides in the Philippines and service of the summons and complaint is pending.

---

ITEM 4. MINE SAFETY DISCLOSURE
Item 4. Mine Safety Disclosures
Not applicable to our Company.
PART II

---

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY
Item 5. Market for Common Equity, Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities
Market Information
Our shares of common stock are quoted on the OTC Markets Group’s Pink® Open Market under the symbol DFCO. Set forth below are high and low bid prices for our common stock for each quarterly period in the two most recent fiscal years. Such quotations reflect inter-dealer prices, without retail mark-up, markdown or commissions and may not necessarily represent actual transactions in the common stock.
Period
High
Low
Fiscal 2024
First Quarter ended September 30, 2023
$ 0.2375
$ 0.2100
Second Quarter ended December 31, 2023
$ 0.4600
$ 0.1850
Third Quarter ended March 31, 2024
$ 0.2070
$ 0.1450
Fourth Quarter ended June 30, 2024
$ 0.2325
$ 0.1535
Fiscal 2023
First Quarter ended September 30, 2022
$ 0.3700
$ 0.0900
Second Quarter ended December 31, 2022
$ 0.1700
$ 0.0700
Third Quarter ended March 31, 2023
$ 0.0200
$ 0.0800
Fourth Quarter ended June 30, 2023
$ 0.1900
$ 0.0600
Number of Holders
As of January 8, 2025, there were 120,157,113 issued and outstanding shares of common stock held by a total of 605 shareholders of record.
Dividends
No cash dividends were paid on our shares of common stock during the fiscal years ended June 30, 2024, and 2023. We have not paid any cash dividends since our inception and do not foresee declaring any dividends on our common stock in the foreseeable future.
Recent Sales of Unregistered Securities
In July 2023, the Company issued 500,000 shares of common stock in connection with a fee for a third-party loan in the amount of 1,200,000. The company ascribed $60,000 to those shares recorded as a debt discount. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In July 2023, the Company issued 109,637 shares of common stock pursuant to the Stock Purchase Agreement with Prakat Solutions Inc. for $14,413. This issuance was a follow on with certain legacy stockholders of Prakat to the 2020 purchase by the Company of 72% of Prakat. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In September and December 2023, April and May 2024, the Company issued a total of 500,000 shares of common stock related to earn-out payments in the acquisition of Genefic Specialty Pharmacy. The company ascribed $106,250 to those shares recorded at the value of the shares upon issuance. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In October 2023 the company issued 500,000 shares of common stock pursuant to a loan agreement for $173,000. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In December 2023 and April 2024, the Company issued a total of 1,000,002 shares of common stock related to the acquisition of DepTec (SSCe) for $200,947. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In February 2024, the Company issued 4,666,665 shares of common stock related to a Company conducted private placement for aggregate proceeds of $604,001, or $0.13 per share. The Company used the proceeds for operating capital. The Company issued these shares of common stock pursuant to the exemption from registration abiding by Rule 506 under Regulation D.
In February 2024, the Company issued 1,200,000 shares of common stock pursuant to consulting agreements resulting in $241,200 in consultancy fees. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
Preferred Stock:
On March 29, 2024, the Company converted $13,318,943 of related party debt principal and interest into 15,951 shares (effective price of $835 per share) of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 3(a)(9) of the Act in that such issuance did not constitute a public offering.
Pursuant to the acquisition agreement dated April 6, 2022 between the Company and Silicon Services Consortium Ltd. (“SSCe”), the sellers of SSCe were to be issued 3,000,000 shares of its common stock evenly every quarter for 24 months with the initial distribution to take place on the effective date (the “Share Consideration”). If at the end of the 24-month stock distribution period, beginning on the effective date of April 7, 2022 (the “Distribution Period”), the value of common stock consideration does not equate to 4,000,000 GBP (the “Target Amount”) in value, then the Company shall issue additional stock equal to the shortfall between the value of the Share Consideration and the Target Amount (the “Valuation Shortfall”). At the end of the Distribution Period, the sellers of SSCe were to be issued an additional $4,440,000 in stock as a result of the Valuation Shortfall. The Company share price at the end of the Distribution Period was $0.20, creating an additional 22,200,000 shares of common stock due to the sellers of SSCe. Pursuant to board resolution dated May 22, 2024, Valuation Shortfall shares were issued into 4,440 shares of Series I Convertible Preferred Stock (“Series I Stock”) as opposed to common stock. The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
On June 30, 2024, the Company converted $3,924,499 of related party debt principal and interest into 4,700 shares (effective price of $835 per share) of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 3(a)(9) of the Act in that such issuance did not constitute a public offering.
Other Stockholder Matters
None.

---

ITEM 6. SELECTED FINANCIAL DATA
Item 6. Selected Financial Data
Not applicable to smaller reporting companies.

---

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis in conjunction with our financial statements, including the notes thereto, included in this Report. Some of the information contained in this Report may contain forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended (the “Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that the projections included in these forward-looking statements will come to pass. Our actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. We undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.
Our Independent Registered Public Accounting Firm’s report contains a statement that our net loss and limited working capital raise substantial doubt about our ability to continue as a going concern. Our independent registered public accountants have stated in their report (included in Item 8 of the Financial Statements) that our significant operating losses and working capital deficit raise substantial doubt about our ability to continue as a going concern. We incurred a net loss of $23,250,181 and 20,627,896, respectively, for the years ended June 30, 2024 and 2023. Although the Company continues to rely on equity and debt investors to finance its losses, it is implementing plans to achieve cost savings and other strategic objectives to address Company profitability. In addition to raising debt and equity financing, the Company continues to focus on growing the subsidiaries anticipated to be most profitable while reducing investments in areas that are not expected to have long-term benefits. The Company will continue to pursue synergistic opportunities to enhance its business portfolio.
Acquisitions
During the year ended June 30, 2024, the Company acquired a business to complement the Genefic segment.
Refer to “Note 4. Business Combinations and Asset Acquisition” to the Condensed Consolidated Financial Statements for discussion regarding the Company’s acquisitions.
RESULTS OF OPERATIONS
The following table sets forth the results of our operations for the years ended June 30, 2024, and 2023:
Year Ended June 30, 2024
Genefic Dalrada Climate Technology Dalrada Precision Manufacturing Dalrada Technologies Corporate Consolidated
Revenues $ 17,684,765 $ 3,674,697 $ 2,447,148 $ 1,373,136 $ - $ 25,179,746
Income (Loss) from Operations (1,825,270 ) (5,956,460 ) (1,349,321 ) (235,104 ) (11,409,690 ) (20,775,845 )
Year Ended June 30, 2023
Genefic Dalrada Energy Dalrada Precision Manufacturing Dalrada Technologies Corporate Consolidated
Revenues $ 15,740,919 $ 7,075,414 $ 4,873,225 $ 2,049,411 $ - $ 29,738,969
Income (Loss) from Operations (5,783,441 ) (1,065,221 ) (2,461,219 ) 10,634 (11,660,710 ) (20,959,957 )
Dalrada Financial Corporation manages five primary segments: 1) Genefic (formerly Dalrada Health); 2) Dalrada Climate Technology; 3) Dalrada Precision Manufacturing; 4) Dalrada Technologies; and 5) Dalrada Corporate. The business segment data (see “Note 13. Segment Reporting”) should be read in conjunction with this discussion.
Revenues and Cost of Revenues
Genefic
Total Revenues for Genefic increased to $17,684,765, or 12.3% from last year’s revenue of $15,740,919.
Genefic Specialty Pharmacy (formerly ‘Watson’) revenue increased $13,049,089, or 453.8% compared to $2,875,326 in the prior year. The increase was a result of obtaining additional accreditations including the Healthcare Merchant Accreditation from the National Association of Boards of Pharmacy (NABP) where it can be listed on the official Accredited Merchants’ list along with larger pharmacy retailers CVS, Walgreens, and Walmart, among others. With Healthcare merchant Accreditation, Genefic Specialty Pharmacy has proven its standards and practices to be in line with the requirements set by large online advertising platforms such as Google and Bing. Genefic Specialty Pharmacy also obtained the Specialty Pharmacy Accreditation and Mail Service Pharmacy Accreditation from the Utilization Review Accreditation Commission (URAC). NABP’s Specialty Pharmacy Accreditation signifies to patients, payers, and providers that the pharmacy organization is recognized for providing an advanced level of pharmacy services and disease management for patients taking medications that meet special handling, storage and distribution requirements. NABP’s Digital Pharmacy Accreditation signifies to patients, payers, and providers that the pharmacy organization is recognized for its commitment to the highest quality health care and safe pharmacy practices over the internet. The specific Digital Pharmacy Accreditation was created to recognize safe and legitimate pharmacies with an internet presence that stands out against the ever-growing list of rogue pharmacy websites. These accreditations allowed Genefic Specialty Pharmacy to ramp up a sales team in conjunction with the ability to fill specialty medications. Lastly, Genefic Specialty Pharmacy was granted a number of hemophilia contracts throughout the year. The cost of revenue was $10,612,296.
Pala Diagnostics (“Pala”) and Empower Genomics (“Empower”) generated $27,910 of the total revenue for Genefic through its complexity CLIA diagnostic laboratories compared with $10,338,768 in the prior year. The decrease in revenue was a result of the closure of the CLIA diagnostic laboratories, which focused primarily on COVID-19 testing services with validated PCR and Rapid antigen testing.
DCI generated $1,338,960, or 7.6% of the total revenue for Genefic. DCI’s revenue increased by $247,026 from the prior year, or 22.6%. The increase in revenue was a result of obtaining Licensed Vocational Nursing (“LVN”) accreditation along with a rising number of students entering and graduating from DCI’s Certified Nursing Assistant (“CNA”), Medical Assistant and Home Health Aid (“HHA”) Certification programs.
Dalrada Precision Manufacturing
Total Revenues for Dalrada Precision Manufacturing decreased to $2,447,148, or 49.8% from last year’s revenue of $4,873,225.
Dalrada Precision Parts generated $1,130,905, or 46.2% of the total revenue for Dalrada Precision Manufacturing. Revenue for Dalrada Precision Parts decreased by $1,550,001, or 57.8% from the prior year. The decrease in revenue was due to the loss of its primary customer in precision parts manufacturing. The cost of revenue was $427,364, or 37.8% of revenue.
DepTec generated $1,242,642, or 50.8% of the total revenue for Dalrada Precision Manufacturing. Revenue for DepTec decreased by $49,661, or 3.8% from the prior year. DepTec records its revenue using a cost-based input method, by which we use actual costs incurred relative to the total estimated contract costs to determine, as a percentage, progress toward contract completion. The cost of revenues was $1,279,752, or 103.0% of revenue.
Ignite’s cleaners, parts washers and degreaser products generated $73,601, or 3.0% of total revenue for Dalrada Precision Manufacturing. Revenue for Ignite decreased by $231,657, or 75.9% from the prior year. The decrease in revenue was due to ramping down operations of the company. The cost of revenue was $77,536, or 105.3% of revenue, and includes inventory adjustments.
Dalrada Climate Technology (Formerly Dalrada Energy Services)
Total Revenues for Dalrada Climate Technology decreased to $3,674,697, or 48.1% from last year’s revenue of $7,075,414.
Dalrada Energy Services generated $567,930, or 15.5% of the total revenue for the Dalrada Climate Technology segment. Revenue for Dalrada Energy Services decreased by $3,943,603, or 87.4% from the prior year. The decrease in revenue was a result of nearing completion of the Averett University project.
Bothof Brothers Construction (“Bothof”) generated $2,796,199, or 76.1% of the total revenue for the Dalrada Climate Technology segment. Bothof revenue increased by $232,318, or 9.1% from last year. Bothof generated revenue in its construction and contracting services throughout the United States. Bothof Brothers’ customers include both residential and commercial projects in the private and public sectors. During the year, $1,697,485 of revenue was generated through related parties. The cost of revenue was $3,176,886, or 113.6% of revenue
Dalrada Technologies
Total Revenue for Dalrada Technologies” sole subsidiary, Prakat, decreased to $1,373,136, or 33.0% from the prior year’s revenue of $2,049,411. The decrease in revenue was a result of several contracts ending their terms during the year.
Operating Expenses
Total Operating Expenses decreased to $26,584,681, or 11.4%, compared to last year’s expenses of $30,019,876.
Corporate
Total Corporate expenses decreased to $11,377,290, or 2.4%, compared to last year’s expenses of $11,660,710.
The Corporate segment’s Selling, general and administrative (“SG&A”) expenses consist of the following:
· Employee compensation and benefits decreased by $522,450, or 12.2% from the prior year and is a result of a reduction in corporate employees.
· Legal and professional fees increased by $396,486, or 39.2% from the prior year and is a result of an increase in corporate litigation as well as audit related costs.
· Sales and marketing costs increased by $27,326, or 36.9% from the prior year due to increased costs associated with third party investor relations, paid media, and content creation expenses.
· Other general and administrative costs for general corporate expenses, including information technology, rent, travel, and insurance decreased by $256,222, or 13.5% from the prior year and is a result of decreased in travel expenses, computer software expenses, and management fees.
Interest Expense decreased by $1,354,290 or 53.0% from the prior year as a result of increases in related party debt as well as PPP loans and convertible debt issued in prior years. See “Note 7. Notes Payable” to our audited condensed consolidated financial statements included in this Annual Report on Form 10-K for more information regarding our outstanding debt.
Stock-based compensation includes expenses related to equity awards issued to employees and non-employee directors. Stock-based compensation increased by $221,440, or 5.5% from the prior year. See “Note 12. Stock-Based Compensation” to our audited condensed consolidated financial statements included in this Annual Report on Form 10-K for more information regarding our stock-based compensation.
Genefic
Total Genefic expenses decreased to $7,266,439, or 36.6%, compared to last year’s expenses of $11,468,627.
The Genefic segment’s Selling, general and administrative (“SG&A”) expenses consist of the following:
· Employee compensation and benefits increased by $1,255,151, or 52.4% from the prior year and a result of growth of the pharmacy business.
· Legal and Professional Fees decreased by $1,764,960, or 71.8% from the prior year and primarily a result of a reduction in professional fees associated with COVID-19 testing services with validated PCR and Rapid antigen testing.
· Sales and marketing costs decreased by $16,314, or 34.8% from the prior year due to reduced costs associated with third party advertising, paid media, and content creation expenses.
· Other general and administrative costs decreased by $3,242,509, or 52.9% from the prior year and is a result of bad debt expense recorded in the prior fiscal year for Boost, Pala, and Genefic Wellness in the amounts of $1,648,562, $1,296,825, and $1,100,675, respectively.
Dalrada Precision Manufacturing
Total Dalrada Precision Manufacturing expenses decreased to $2,011,817, or 51.4%, compared to last year’s expenses of $4,136,885.
The Dalrada Precision Manufacturing Segment’s Selling, general and administrative (“SG&A”) expenses consist of the following:
· Employee compensation and benefits decreased by $1,035,630 or 70.4% from the prior year as a reduced activity in the segment.
· Legal and Professional Fees decreased by $1,019,258, or 89.2% from the prior year. The decrease in legal fees was primarily a result of the settlement Likido Ltd.’s lawsuit with MAPtech Packaging, Inc. Pursuant to the settlement, the Company shall pay the sum of $558,252 in damages, legal costs, and reimbursement for arbitration fees and expenses paid on account by MAPtech recognized in the prior year.
· Sales and marketing costs decreased by $2,246, or 13.3% from the prior year due to reduced costs associated with third party advertising, paid media, and content creation expenses.
· Other general and administrative costs decreased by $67,934, or 4.5% from the prior year and is a result of a decrease in travel, trade shows and other overhead expenses required for the expansion in the Precision Parts and Ignite businesses.
Dalrada Climate Technology
Total Dalrada Climate Technology expenses increased to $5,204,881, or 164.2%, compared to last year’s expenses of $1,969,829.
The Dalrada Climate Technology Segment’s Selling, general and administrative (“SG&A”) expenses consist of the following:
· Employee compensation and benefits increased to $2,878,201, compared to $484,719 in the prior year as the energy segment continued to grow during the year. The employee resources were focused on the development of the current projects and building a future pipeline.
· Legal and Professional Fees decreased by $292,415, or 51.0% from the prior year and is a result of the growth of the energy segment throughout the prior year. Professional fees included services for management fees and other services specific to the energy industry.
· Sales and marketing costs increased to $19,988, a 58.6% increase from the prior year. The Company’s internal marketing generates most of the sales and marketing services which is included in the Corporate segment employee compensation and benefits expenses.
· Other general and administrative costs increased to $2,026,225, a 125.2% increase from the prior year and is a result of management fees, travel and other general overhead costs associated with Dalrada Climate Technology’s energy upgrade business and Bothof Brothers Contracting.
Dalrada Technologies
Total Dalrada Technologies expenses decreased to $724,254, or 7.6%, compared to last year’s expenses of $783,825.
The Dalrada Technologies segment’s Selling, general and administrative (“SG&A”) expenses consist of the following:
· Employee compensation and benefits decreased by $51,363, or 15.1% from the prior year and is a result of employee wage fluctuations.
· Legal and Professional Fees increased by $51,158, or 37.2% from the prior year and is a result of increased third-party engineering fees related to its projects.
· Sales and marketing costs increased by $15,844, or 1,039.0% from the prior year and is a result of increased third-party advertising and marketing costs.
· Other general and administrative costs decreased by $75,210, or 24.7% and is a result of decreases in information technology, rent, travel, and insurance costs.
Other (Expense) Income
Other (Expense) Income increased by $2,806,572 or 844.8% from a $332,236 in Other Income in the prior year to a $2,474,336 Other Expense in the current year. The change in Other Expense was a result of $2,090,978 of “Gain on expiration of accrued payroll taxes” due to quarterly tax liabilities that expiring during fiscal 2023, $500,000 related to the sale of the Dalrada Energy Services intellectual property, and a $585,411 change in the fair value of contingent liability all incurred in the prior year. Other expenses incurred for the fiscal year ended June 30, 2024 consisted of interest expense of $1,213,441 and a change in fair value of the contingent liability of $511,892.
Net Income (Loss)
Net loss for the year ended June 30, 2024, was $23,250,181 compared to a Net loss of $20,627,721 during the year ended June 30, 2023.
Liquidity and Capital Resources
As of June 30, 2024, the Company had current assets of $13,145,412 and current liabilities of $13,844,784 compared with current assets of $9,817,045 and current liabilities of $10,019,465 at June 30, 2023. The continuation of the Company as a going concern is dependent upon successful financing through equity and/or debt investors and growing the subsidiaries anticipated to be profitable while reducing investments in areas that are not expected to have long-term benefits.
The Company anticipates an increase in sales of Likido’s Likido®ONE heat pump through its current and future customer base. Furthermore, the United States General Services Administration (GSA) and the Department of Energy (DOE) have chosen the Company’s Likido®ONE heat pump to help reduce greenhouse emissions from commercial buildings through high performance, low-carbon solutions set forth by the Green Proving Ground (GPG) program.
Cash Flows
Year Ended
June 30,
Net cash used in operating activities $ (7,925,238 ) $ (4,612,798 )
Net cash used in investing activities (552,658 ) (1,063,427 )
Net cash provided by financing activities 8,117,078 5,717,144
Net change in cash during the period, before effects of foreign currency $ (360,818 ) $ 40,919
Cash flow from Operating Activities
During the year ended June 30, 2024, the Company used $7,925,238 of cash for operating activities compared to $4,612,798 used during the year ended June 30, 2023. The increase in the use of cash for operating activities was primarily due to an overall increase in funding from related parties.
Cash flow from Investing Activities
During the year ended June 30, 2024, the Company used $552,658 of cash for investing activities compared to $1,063,427 used during the year ended June 30, 2023. The decrease in the use of cash for investing activities was due to the purchase of property plant and equipment in the prior year.
Cash flow from Financing Activities
During the year ended June 30, 2024, the Company received $8,117,078 of cash for financing activities compared to $5,717,144 received during the year ended June 30, 2023. The increase in financing activities was primarily due to the draw down of various note payables to fund the company.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, Revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Subsequent Events
On July 10, 2024, the Company entered into a promissory note with 1800 Diagonal Lending, LLC for $87,975. The promissory note includes a one-time interest charge of 14%, which was applied on the issuance date, and matures on May 15, 2025. There are 4 monthly payments of $10,029 and one payment of $60,175 for a total payback of $100,291.
On July 18, 2024, the Company executed a cash advance agreement with Cali Flower Capital Inc. with a total advance of $200,00 and payback of $299,800.
On July 25, 2024, the Company executed a revenue purchase agreement with 24 Capital with a total advance of $125,000 and payback of $187,375.
On July 29, 2024, the Company executed a revenue purchase agreement with Tycoon Capital Group with a total advance of $125,000 and payback of $187,375.
On August 12, 2024, the Company entered into an Exclusive Master Distribution Agreement (the “Agreement”) with Applied Technologies of NY, Inc. (“ATI”). The Agreement establishes the sales goals of 50 commercial heat pumps and 25 residential heat pumps in the first 18 months followed by a total of 600 heat pumps (combined commercial and residential heat pumps) in the following 12-month period.
On August 15, 2024, the Company signed a lease for 5,650 square feet of manufacturing and office space in Portland, Oregon related to the deposition technology business. The base monthly lease cost is $5,254 per month and expires on April 30, 2027.
On August 19, 2024, the Company acquired Grand Entrances for the consideration of $100 in cash, including its current liabilities and assuming its lease, which includes a monthly lease cost of $10,291 and expires on April 11, 2030.
On August 23, 2024, the Company executed a revenue purchase agreement with Quick Funding with a total advance of $170,000 and payback of $254,150.
On September 20, 2024, the Company executed a revenue purchase agreement with QFS Capital, LLC with a total advance of up to $1,573,781 and payback of $2,359,097.
On October 11, 2024, Vince Monteparte resigned as a member of the Company’s Board of Directors.
On October 12, 2024, Assurance Dimensions resigned as the Company’s auditor.
On October 15, 2024, Heather McMahon resigned as member of the Company’s Board of Directors.
On October 18, 2024, the Company engaged CM3 Advisory as its new auditor for the fiscal year ended June 30, 2024.
On October 23, 2024, the Company nominated Roger Campos as a member of the Company’s Board of Directors.
Critical Accounting Policies
Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America and applied on a consistent basis. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.
We regularly evaluate the accounting policies and estimates that we use to prepare our condensed consolidated financial statements. A complete summary of these policies is included in Note 2. Summary of Significant Accounting Policies of the notes to our condensed consolidated financial statements. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.
Accrued Payroll Taxes
The total balance for Federal Accrued Payroll Taxes is accumulated on a quarterly basis beginning on their respective quarterly filing dates. Accrued Interest is compounded daily at an Effective Annual Interest Rate of approximately seven percent. The individual quarterly sub-totals have a calculated expiration date of ten years according to the Internal Revenue Service (“IRS”) statute of limitations. This timeline can be extended because of bankruptcy or other legal action that is filed by the Company (Code 520 per IRS Federal Account Transcripts). Code 520 effectively stops the clock for the Statute of limitations until the bankruptcy or other legal action has been removed (Code 521 per IRS Federal Account Transcripts). In addition to the number of days between Code 520 and 521, every Code 520 automatically extends the IRS Statute of limitations by 30 days. As the quarterly sub-totals surpass their respective “Calculated Expiration Date” the Company removes the liability from the Condensed Consolidated Balance Sheets and an equivalent amount is recognized as “Gain on expiration of accrued payroll taxes” on the Condensed Consolidated Statements of Operations and Comprehensive Loss. The amount owing may be subject to additional late filing fees and penalties that are not quantifiable as at the date of these condensed consolidated financial statements.
Revenue Recognition
The Company recognizes and accounts for revenue in accordance with Accounting Standards Codification (“ASC”) 606 as a principal on the sale of goods and services. Pursuant to ASC 606, revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies its performance obligation by transferring control over a product or service to a customer.
Use of Estimates
Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the revenue, valuation of inventory, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, litigation, and evaluation of goodwill and intangible assets for impairment.
The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Stock-Based Compensation
The Company records stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value using quoted market prices of the equity instruments issued.
Business Combination
ASC 805, Business Combinations (“ASC 805”), applies the acquisition method of accounting for business combinations to all acquisitions where the acquirer gains a controlling interest, regardless of whether consideration was exchanged. ASC 805 establishes principles and requirements for how the acquirer: a) recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree; b) recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and c) determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. Accounting for acquisitions requires the Company to recognize, separately from goodwill, the assets acquired, and the liabilities assumed at their acquisition-date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the net of the acquisition-date fair values of the assets acquired and the liabilities assumed. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded with a corresponding gain or loss being recognized in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
Goodwill and Intangible Assets
The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles - Goodwill and Other (“ASC 350”). ASC 350 requires that goodwill and other intangibles with indefinite lives should be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value.
Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (June 30 for the Company) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. The Company considers its market capitalization and the carrying value of its assets and liabilities, including goodwill, when performing its goodwill impairment test. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company's reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit's goodwill and if the carrying value of the reporting unit's goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company recorded an impairment of goodwill in the amount of $0 and $433,556 during the years ended June 30, 2024 and 2023, respectively.
An intangible asset is an identifiable non-monetary asset without physical substance. Such an asset is identifiable when it is separable, or when it arises from contractual or other legal rights. Separable assets can be sold, transferred, licensed, etc. Examples of intangible assets include computer software, licenses, trademarks, patents, films and copyrights. The Company’s intangible assets are finite lived assets and are amortized on a straight-line basis over the estimated useful lives of the assets.
Purchase Price Allocation
Upon the completion of a business combination, the consideration transferred as well as the assets and liabilities acquired must be recorded at their acquisition date fair values. Upon identification of the acquirer and determination of the acquisition date, business combinations are accounted for through the preparation of a Purchase Price Allocation (PPA). We take into consideration the five steps when completing a PPA:
Step 1: Determine the fair value of consideration paid;
Step 2: Revalue all existing assets and liabilities (excluding intangible assets and goodwill which are addressed in step 3 to 5 below) to their acquisition date fair values;
Step 3: Identify the intangible assets acquired;
Step 4: Determine the fair value of identifiable intangible assets acquired; and,
Step 5: Allocate the remaining consideration to goodwill and assess the reasonableness of the overall conclusion
Related Party Transactions
Related party transactions are conducted with parties with which the Company has a close association, such as majority owned subsidiaries, its executive, managers, and their families. The types of transactions that can be conducted between related parties are many, such as sales, asset transfers, leases, lending arrangements, guarantees, allocations of common costs, and the filing of consolidated tax returns. The Company discloses any transaction that would impact the decision making of the users of its condensed consolidated financial statements. This involves the following disclosures:
· General. The Company discloses all material related party transactions, including the nature of the relationship, the nature of the transactions, the dollar amounts of the transactions, the amounts due to or from related parties.
· Receivables. The Company separately discloses any receivables from officers, employees, or affiliated entities.
Recently Issued Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending June 30, 2025.
Contractual Obligations
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

---

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Item 7A. Quantitative and Qualitative Disclosures about Market Risk
Not applicable to smaller reporting companies.

---

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Item 8. Financial Statements
DALRADA FINANCIAL CORPORATION
Consolidated Financial Statements
For the Years Ended June 30, 2024 and 2023
Report of Independent Registered Public Accounting Firm
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
Condensed Consolidated Statements of Cash Flows
Notes to the Condensed Consolidated Financial Statements
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
[EXPLANATORY NOTE]
The financial statements contained in this Annual Report on Form 10-K meet the Alternative Reporting Standards of the OTC Markets Group Inc. and are believed by management to fairly present the financial statements of the Company as at June 30, 2024 and for the 12 months then ended. However, they are deficient as an annual report filed under Section 13 of the Securities Exchange Act of 1934 because such financial statements do not contain a report of the Company’s PCAOB registered independent public accounting firm. As of the date of this filing, that firm had not completed its audit procedures in respect of the Company’s financial statements for the fiscal year ended June 30, 2024; hence, no report was included in this filing. The Company plan to remedy this deficiency through the filing of an amended Annual Report on Form 10-K as promptly as possible, which amendment will include an audit report and a footnote to the Company’s financial statements that will explain in tabular form any variances between this filing and the amended filing.
DALRADA FINANCIAL CORPORATION
Condensed Consolidated Balance Sheets
June 30, June 30,
(Unaudited)
Assets
Current assets:
Cash and cash equivalents $ 501,927 $ 812,806
Accounts receivable, net 7,403,933 4,453,104
Accounts receivable, net - related parties 1,236,484 752,348
Other receivables 680,598 376,604
Inventories 2,647,652 2,078,692
Prepaid expenses and other current assets 674,818 1,343,491
Total current assets 13,145,412 9,817,045
Noncurrent receivables 20,742 41,722
Noncurrent receivables - related parties 1,136,508 1,173,893
Property and equipment, net 1,452,282 1,476,082
Goodwill 4,175,758 3,803,147
Intangible assets, net 3,547,266 3,858,086
Right-of-use asset, net 2,437,034 2,771,854
Right-of-use asset, net - related party 1,689,806 2,227,286
Total assets $ 27,604,808 $ 25,169,115
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 6,382,691 $ 5,178,897
Accrued liabilities 1,023,286 1,084,008
Accounts payable and accrued liabilities - related parties 136,976 547,949
Deferred revenue 452,411 1,337,259
Notes payable, current portion 4,468,760 439,562
Notes payable, current portion - related parties - 251,605
Lease liability, current portion 832,142 660,394
Lease liability, current portion - related party 548,518 519,791
Total current liabilities 13,844,784 10,019,465
Noncurrent payables - 48,888
Notes payable, net of current portion 2,332,003 1,011,395
Notes payable, net of current portion - related parties 53,957 1,648,478
Contingent consideration 47,343 4,285,389
Lease liability, net of current portion 1,694,804 2,160,834
Lease liability, net of current portion - related party 1,193,312 1,741,830
Total liabilities 19,166,203 20,916,279
Commitments and contingencies (Note 13) - -
Stockholders' equity:
Preferred stock, $0.01 par value, 100,000 shares authorized: - -
Series I preferred stock, $0.01 par value, 51,059 and 35,108 shares authorized, issued and outstanding as of June 30, 2024 and June 30, 2023, respectively
Series H preferred stock, $0.01 par value, 15,002 shares authorized, issued and outstanding as of June 30, 2024 and June 30, 2023, respectively
Series G preferred stock, $0.01 par value, 10,002 shares authorized, issued and outstanding as of both June 30, 2024 and June 30, 2023, respectively
Series F preferred stock, $0.01 par value, 5,000 shares authorized, issued and outstanding as of both June 30, 2024 and June 30, 2023, respectively
Common stock, $0.005 par value, 500,000,000 shares authorized, 97,175,443 and 88,699,139 shares issued and outstanding at June 30, 2024 and June 30, 2023, respectively 485,877 443,478
Common stock to be issued - 192,925
Preferred stock to be issued 21,839,776 -
Additional paid-in capital 150,948,583 145,251,822
Accumulated deficit (164,741,349 ) (141,729,009 )
Accumulated other comprehensive loss (909 ) (50,848 )
Total Dalrada Financial Corp's stockholders' equity 8,532,629 4,109,019
Noncontrolling interests (94,024 ) 143,817
Total stockholders' equity 8,438,605 4,252,836
Total liabilities and stockholders' equity $ 27,604,808 $ 25,169,115
(The accompanying notes are an integral part of these condensed consolidated financial statements)
DALRADA FINANCIAL CORPORATION
Condensed Consolidated Statements of Operations and Comprehensive Loss
Year Ended
June 30,
Revenues $ 23,461,914 $ 27,456,223
Revenues - related party 1,717,832 2,282,746
Total revenues 25,179,746 29,738,969
Cost of revenues 19,370,910 20,679,050
Gross profit 5,808,836 9,059,919
Operating expenses:
Selling, general and administrative 26,584,681 29,466,320
Research and development - 120,000
Loss on impairment of goodwill - 433,556
Total operating expenses 26,584,681 30,019,876
Loss from operations (20,775,845 ) (20,959,957 )
Other (expense) income:
Interest expense (1,213,441 ) (2,552,918 )
Interest income 85,659 79,758
Other (expense) income (1,340,147 ) 722,620
Gain on expiration of accrued tax liability - 2,090,978
(Loss) gain on foreign exchange (6,407 ) (8,202 )
Total other (expense) income, net (2,474,336 ) 332,236
Loss before taxes (23,250,181 ) (20,627,721 )
Income taxes - -
Net loss (23,250,181 ) (20,627,721 )
Other comprehensive loss
Foreign currency translation 49,939 (175 )
Comprehensive loss $ (23,200,242 ) $ (20,627,896 )
Net loss attributable to noncontrolling interests (237,841 ) (335,202 )
Net loss attributable to Dalrada Financial Corporation stockholders $ (23,012,340 ) $ (20,292,519 )
Net loss per common share to Dalrada stockholders - basic $ (0.25 ) $ (0.24 )
Net loss per common share to Dalrada stockholders - diluted $ (0.25 ) $ (0.24 )
Weighted average common shares outstanding - basic 92,135,080 83,761,903
Weighted average common shares outstanding - diluted 92,135,080 83,761,903
(The accompanying notes are an integral part of these condensed consolidated financial statements)
DALRADA FINANCIAL CORPORATION
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
Preferred Stock
Series I Series H Series G Series F Common Stock
Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount
Balance at June 30, 2023 35,108 $ 351 15,022 $ 150 10,002 $ 100 5,000 $ 50 88,699,139 $ 443,478
Common stock issued pursuant to acquisitions - - - - - - - - 1,609,639 8,048
Common stock issued pursuant to debt agreement - - - - - - - - 1,000,000 5,000
Conversion of related party notes into preferred stock - - - - - - - - - -
Warrants issued pursuant to acquisitions - - - - - - - - - -
Common stock issued pursuant to consulting agreement - - - - - - - - 1,200,000 6,000
Common stock issued pursuant to private placement - - - - - - - - 4,666,665 23,351
Stock-based compensation - - - - - - - - - -
Net loss - - - - - - - - - -
Foreign currency translation - - - - - - - - - -
Balance at June 30, 2024 35,108 $ 351 15,022 $ 150 10,002 $ 100 5,000 $ 50 97,175,443 $ 485,877
Preferred Stock
Series I Series H Series G Series F Common Stock
Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount
Balance at June 30, 2022 - $ - - $ - 10,002 $ 100.00 5,000 $ 50 72,174,620 $ 360,855
Common stock issued for conversion of convertibles notes, accrued interest and premium - - - - - - - - 10,974,520 54,873
Common stock issued pursuant to acquisitions - - - - - - - - 3,049,999 15,250
Common stock issued pursuant to consultant agreement - - - - - - - - 2,000,000 10,000
Conversion of related party notes into preferred stock 35,108 15,022 - - - - - -
Warrants issued pursuant to acquisitions - - - - - - - - - -
Stock-based compensation - - - - - - - - 500,000 2,500
Net income (loss) - - - - - - - - - -
Foreign currency translation - - - - - - - - - -
Balance at June 30, 2023 35,108 $ 351 15,022 $ 150 10,002 $ 100 5,000 $ 50 88,699,139 $ 443,478
(Continued)
(The accompanying notes are an integral part of these condensed consolidated financial statements)
DALRADA FINANCIAL CORPORATION
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
(continued)
Common Stock to be Preferred Stock to be Additional Paid-in Accumulated Accumulated Other Comprehensive Income Total
Dalrada
Financial
Corp's Stockholders'
Noncontrolling Total Stockholders' Equity
Issued Issued Capital Deficit (Loss) Deficit Interests (Deficit)
Balance at June 30, 2023 192,925 - $ 145,251,822 $ (141,729,009 ) $ (50,848 ) $ 4,109,019 $ 143,817 $ 4,252,836
Common stock issued pursuant to acquisitions (192,925 ) 4,596,334 386,093 - - 4,797,550 - 4,797,550
Common stock issued pursuant to debt agreement - - 228,000 - - 233,000 - 233,000
Conversion of related party notes into preferred stock - 17,243,442 - - - 17,243,442 - 17,243,442
Warrants issued pursuant to acquisitions - - 22,722 - - 22,722 - 22,722
Common stock issued pursuant to consulting agreement - - 235,200 - - 241,200 - 241,200
Common stock issued pursuant to private placement - - 580,650 - - 604,001 - 604,001
Stock-based compensation - - 4,244,096 - - 4,244,096 - 4,244,096
Net loss - - - (23,012,340 ) - (23,012,340 ) (237,841 ) (23,250,181 )
Foreign currency translation - - - - 49,939 49,939 - 49,939
Balance at June 30, 2024 - 21,839,776 $ 150,948,583 $ (164,741,349 ) $ (909 ) $ 8,532,629 $ (94,024 ) $ 8,438,605
Common Stock to be Preferred Stock to be Additional Paid-in Accumulated Accumulated Other Comprehensive Income Total
Dalrada
Financial
Corp's Stockholders'
Noncontrolling Total Stockholders' Equity
Issued Issued Capital Deficit (Loss) Deficit Interests (Deficit)
Balance at June 30, 2022 1,066,925 - $ 104,627,032 $ (121,436,490 ) $ (50,673 ) $ (15,432,201 ) $ 479,019 $ (14,953,182 )
Common stock issued for conversion of convertibles notes, accrued interest and premium - - 1,392,615 - - 1,447,488 - 1,447,488
Common stock issued pursuant to acquisitions (699,000 ) - 998,225 - - 314,475 - 314,475
Common stock issued pursuant to consultant agreement - - 174,000 - - 184,000 - 184,000
Conversion of related party notes into preferred stock - - 33,859,043 - - 33,859,544 - 33,859,544
Warrants issued pursuant to acquisitions - - 5,751 - - 5,751 - 5,751
Stock-based compensation (175,000 ) - 4,195,156 - - 4,022,656 - 4,022,656
Net income (loss) - - - (20,292,519 ) - (20,292,519 ) (335,202 ) (20,627,721 )
Foreign currency translation - - - - (175 ) (175 ) - (175 )
Balance at June 30, 2023 192,925 - $ 145,251,822 $ (141,729,009 ) $ (50,848 ) $ 4,109,019 $ 143,817 $ 4,252,836
(The accompanying notes are an integral part of these condensed consolidated financial statements)
DALRADA FINANCIAL CORPORATION
Condensed Consolidated Statements of Cash Flows
Year Ended
June 30,
Cash flows from operating activities:
Net loss $ (23,250,181 ) $ (20,627,721 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 885,965 707,572
Stock compensation 4,244,096 4,022,656
Stock consideration issued to vendor 241,200 184,000
Amortization of debt discount - 1,224,472
Convertible debt premium satisfied with common stock - 200,000
Change in fair value of contingent consideration 752,429 (270,936 )
Provision for credit losses 2,175,397 4,783,357
Loss on impairment of goodwill - 433,556
Gain on expiration of accrued tax liability - (2,090,978 )
Changes in operating assets and liabilities, net of amounts acquired or assumed in connection with acquisition:
Accounts receivable (5,610,362 ) (3,897,875 )
Other receivables (303,994 ) (60,660 )
Inventories (568,960 ) (454,071 )
Prepaid expenses and other current assets 726,900 (722,147 )
Noncurrent receivables 58,365 35,883
Accounts payable 1,203,794 2,822,813
Noncurrent payables (48,888 ) (71,646 )
Accounts payable and accrued liabilities - related parties 12,254,613 7,936,820
Accrued liabilities 199,236 640,529
Accrued payroll taxes, penalties and interest - 35,242
Deferred revenue (884,848 ) 556,336
Net cash used in operating activities (7,925,238 ) (4,612,798 )
Cash flows from investing activities:
Purchase of property and equipment (434,845 ) (693,201 )
Purchase of intangibles (117,813 ) (470,680 )
Acquisition of business, net of cash - 100,454
Net cash used in investing activities (552,658 ) (1,063,427 )
Cash flows from financing activities:
Proceeds from related party notes payable 2,923,418 6,757,688
Repayments of related party notes payable (428,924 ) 350,028
Repayments of convertible note payable - (1,680,000 )
Proceeds from notes payable 6,262,536 -
Repayments of notes payable (1,243,953 ) -
Net proceeds (repayments) from notes payable - 289,428
Proceeds from private placement 604,001 -
Net cash provided by financing activities 8,117,078 5,717,144
Net change in cash and cash equivalents (360,818 ) 40,919
Effect of exchange rate changes on cash 49,939 (175 )
Cash and cash equivalents at beginning of period 812,806 772,062
Cash and cash equivalents at end of period $ 501,927 $ 812,806
Supplemental disclosure of cash flow information:
Cash paid for income taxes $ - $ 139,941
Cash paid for interest $ 621,735 $ 53,760
Supplemental disclosure of non-cash investing and financing activities:
Conversion of related party notes and interest into preferred stock $ 14,878,016 $ 33,859,544
Conversion of accounts payable-related parties to note payable-related parties $ 2,365,426 $ 8,676,605
Common stock issued pursuant to business combination $ 70,936 $ 314,475
Conversion of convertible note payable, accrued interest and premium into common stock $ - $ 1,447,488
Warrants issued pursuant to acquisitions $ 22,722 $ -
Net assets acquired upon acquisition $ 371,298 $ -
(Decrease) Increase in right-of-use asset and liability $ (58,227 ) $ 2,227,830
(The accompanying notes are an integral part of these condensed consolidated financial statements)
DALRADA FINANCIAL CORPORATION
Notes to the Condensed Consolidated Financial Statements
Years ended June 30, 2024, and 2023
1. Organization and Nature of Operations
Unless otherwise stated or the context requires otherwise, references herein to the “Company,” “Dalrada,” “we,” “us,” and “our” mean Dalrada Financial Corporation and its direct and indirect subsidiaries, and controlled and managed entities.
Dalrada Financial Corporation, (“Dalrada”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTC: DFCO.
Dalrada has five primary business divisions: Genefic, Dalrada Climate Technology, Dalrada Precision Manufacturing, Dalrada Technologies and Dalrada Corporate. Within each of these divisions, the Company drives transformative innovation while creating solutions that are sustainable, accessible, and affordable. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.
Genefic
Genefic delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, When the world needs advanced health care, Genefic delivers with ingenuity, accessibility, and affordability. This specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity- on a global level.
Genefic Specialty Pharmacy (“Genefic Pharmacy”)- Genefic Pharmacy (formerly Genefic Specialty Pharmacy Rx Solutions) is an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Genefic Pharmacy specializes in providing expert care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions. Genefic Pharmacy maintains pharmacy licenses in all 50 States as well as Washington D.C.
Genefic Infusion Rx- Genefic Infusion Rx is a Louisiana-based infusion pharmacy which handles all aspects of fluid and medication infusion, via intravenous or subcutaneous application. Genefic Infusion Rx serves as an essential with healthcare systems, enhancing the infusion process through efficient authorization and prescription management. Its state-of-the-art compounding facility is led by one of only eight pharmacists in Louisiana with a sterile compounding board certification, ensuring top-tier precision and quality in medication preparation.
Boost Diagnostics- Boost Diagnostics (formerly Empower Genomics and Genefic Diagnostics) is Dalrada’s wholly owned diagnostic laboratory subsidiary which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Boost Diagnostics has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Boost Diagnostics also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.
Pala Diagnostics (“Pala”)- Pala was a joint venture diagnostic laboratory entity which processed both molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Pala was no longer an operational entity as of June 30, 2023.
Dalrada Career Institute (“DCI”) (aka International Health Group (“IHG”)) - IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility. DCI started its first RN, nursing class in February of 2024 and this first class will be completed in December 2024. It is the intent of DCI to double their class size when they begin their second class in 2025.
Dalrada Climate Technology (formerly Dalrada Energy Services)
Dalrada Climate Technology (“DCT”) is a segment which incapsulates energy services and state-of-the-art technology within the climate sustainability space. DCT employs next-generation technology and services which enhances clean energy efforts while reducing the world’s carbon footprint. As a premier industrial heat pump manufacturer, Dalrada delivers innovation and efficiency, building solutions that reduce energy consumption and minimize carbon footprints, increase operational efficiencies, meet environmental, social, and governance (ESG) goals, and lower energy costs for clients.
Dalrada Technology Limited (“DTL”)- DTL is a holding company for all United Kingdom and European based Dalrada Climate Technology entities.
Likido Ltd. (“Likido”)- Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. Likido’s products currently include the DCT One Heat Pumps (formerly Likido®ONE) and DCT Cryo Chiller. Likido also offers heat pump solutions specifically designed for residential purposes.
During the prior year, the U.S. Government selected DCT One Series high-performance, low-carbon heat pump for real-world testing in a prestigious clean energy program. The implementation of the DCT One Series testing is still in process. The expected positive results should not only increase market acceleration and adoption within the federal government acceptance of groundbreaking eco-friendly technology but should also accelerate adoption within the commercial building industry.
Dalrada Technology Spain L.T. (“DTS”)- DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing and sale of the DCT One Series and DCT Cryo Chiller throughout Europe.
Dalrada Energy Services (“DES”)- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity. DES helps organizations meet ESG goals and standards while mitigating negative environmental impacts.
Bothof Brothers Construction (“Bothof”)- Bothof is a licensed general contractor which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting, the DES division can provide a myriad of additional services to its private and public works customers.
Dalrada Home Corporation (“Dalrada Home”)- Dalrada Home Corporation was established in February of 2024. Dalrada Home’s cutting-edge sustainability solutions are designed specifically for residential purposes. Our home heat pumps help us lead the way in providing innovative climate technology products and services to residential customers.
Dalrada Precision Manufacturing
Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.
Dalrada Precision Parts (“Precision”) - Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.
Deposition Technologies (“DepTec”) - DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.
DepTec has built an impressive catalogue of precision OEM parts for PVD (Physical vapor deposition) systems and the Company’s refurbished systems which allows clients the option of purchasing the same model of system they’ve been using for decades -but with significant upgrades and improved efficiencies. Older systems can now operate more reliably with additional control and monitoring plus longer lifespans. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs.
Ignite I.T. (“Ignite”) - Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meets or exceed the most stringent industry-testing specifications.
Dalrada Technologies
Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.
Prakat (“Prakat”)- Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.
Dalrada Corporate
Dalrada Corporate covers the activities which support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal advice, information technology, and marketing. It also contains executive management and shareholder-related services.
Going Concern
These condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of June 30, 2024, and 2023, the Company had a positive working capital deficit of $377,228 and $202,420, respectively. The Company incurred negative cash flows from operations for the years ended June 30, 2024, and 2023, and raises substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company as a going concern is dependent upon the successful financing through equity and/or debt investors and growing the subsidiaries anticipated to be profitable while reducing investments in areas that are not expected to have long-term benefits. The Company expects to fund any short-term operational deficits primarily through collection of outstanding accounts receivable from medical insurance providers, Medicare, pharmaceutical sales, the sale of DCT commercial and residential heat pumps as well as loans from related parties.
2. Summary of Significant Accounting Policies
(a) Basis of Presentation
These condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is June 30.
(b) Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its subsidiaries, as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with Accounting Standards Codification (“ASC”) 810 Consolidation. All transactions and balances between these entities have been eliminated upon consolidation.
The condensed consolidated financial statements include the accounts of Dalrada Financial Corporation, Solas Corp., Boost Genomics Inc. (formerly Empower Genomics, Inc.), Dalrada Career Institute (formerly International Health Group, Inc.), Pala Diagnostics, LLC, Pacific Stem Cells, LLC, Genefic Specialty Rx (formerly Genefic Specialty Pharmacy Rx Solutions, Inc.),Genefic Infusion Rx., Shark Innovative Technologies Corp., Dalrada Precision Corp., Dalrada Energy Services, Inc., Dalrada Home Corp., Likido Corp., Dalrada Technology Spain S.L., Ignite I.T., Bothof Brothers Construction Inc., Prakat Solutions, Inc., Prakat Solutions Private Limited, Likido Ltd., Deposition Technologies Ltd. and Dalrada Technology Ltd., controlled by the Company through its direct or indirect ownership of a majority voting interest. Additionally, the condensed consolidated financial statements include the accounts of variable interest entities (“VIEs”) in which the Company has a variable interest and for which the Company is the “primary beneficiary” as it has both: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE. All significant intercompany accounts and transactions are eliminated in consolidation.
Income attributable to the minority interest in the Company’s majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling interests in the Condensed Consolidated Statements of Operations and Comprehensive Loss and the noncontrolling interest is reflected as a separate component of the statement of stockholders’ equity, condensed consolidated balance sheet, and statement of cash flows.
(c) Use of Estimates
The preparation of these condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the revenue, valuation of inventory, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, litigation, and evaluation of goodwill and intangible assets for impairment.
The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
(d) Cash and Cash Equivalents
Cash and cash equivalents include cash deposits in financial institutions, and the Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.
(e) Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
When estimating its allowance for credit losses related to revenues from COVID-19 Testing, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Management considers various historical collection factors for assessing collectability and determining net revenues and accounts receivable from our customers which include the period that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.
During the year ended June 30, 2024 and 2023, healthcare insurers and government payers accounted for over 61% and 42% of total revenues, respectively. Also, healthcare insurers and government payers amounted to total revenues of $17,543,688 and $12,546,849 for the years ended June 30, 2024 and 2023, respectively. The accounts receivable related to both healthcare insurers and government payers is $6,613,175 and $1,499,415 as of June 30, 2024 and 2023, respectively.
As of June 30, 2024 and 2023, $0 and $829,239 is owed by customers from the sale of Likido units, respectively.
(f) Fair Value Measurements
Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:
Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their short-term nature and respective maturity dates or durations.
The fair value of the contingent consideration obligations was based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement was based on significant inputs that were not observable in the market, therefore, the Company classified this liability as Level 3 in the following tables:
Schedule of fair value measurements
Fair Value Measurements
as of June 30, 2024 Using:
Level 1 Level 2 Level 3 Total
Liabilities:
Contingent consideration - - $ 47,343 $ 47,343
$ - $ - $ 47,343 $ 47,343
Fair Value Measurements
as of June 30, 2023 Using:
Level 1 Level 2 Level 3 Total
Liabilities:
Contingent consideration - - $ 4,285,389 $ 4,285,389
$ - $ - $ 4,285,389 $ 4,285,389
The Company records a contingent consideration liability relating to stock price guarantees included in its acquisition and consulting agreements. The estimated fair value of the contingent consideration is recorded using a significant observable measure and is therefore classified as a Level 3 financial instrument.
The fair value of the contingent consideration liability related to the Company’s business combinations is valued based on a forward contract and the guaranteed equity value at settlement as defined in the acquisition agreement (see “Note 4. Business Combinations and Asset Acquisition). The fair value of the contingent consideration is then calculated based on the guaranteed equity value at settlement as defined in the acquisition agreement. (See “Note 14. Commitments and Contingencies”).
Changes in contingent consideration liability during the year ended June 30, 2024, and 2023, are as follows:
Schedule of contingent consideration liability
Contingent
Consideration
Liability
Balance as of June 30, 2023 $ 4,285,389
Change in fair value 310,945
Transfer of contingent liability to current liability (4,596,334 )
Recognition of contract contingencies 47,343
Balance as of June 30, 2024 $ 47,343
Contingent
Consideration
Liability
Balance as of June 30, 2022 $ 4,870,800
Change in fair value (585,411 )
Balance as of June 30, 2023 $ 4,285,389
(g) Convertible Instruments
The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities (“ASC 815”).
Applicable U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
The Company accounts for convertible instruments (when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments) as follows. The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the shares.
(h) Accounts Receivable
Accounts receivables are derived from products and services delivered to customers and are stated at their net realizable value. Each month, the Company reviews its receivables on a customer-by-customer basis and evaluates whether an allowance for expected credit losses is necessary based on any known or perceived collection issues. Any balances that are eventually deemed uncollectible are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of June 30, 2024, and 2023, the Company had an allowance for expected credit losses of $860,200 and $2,430,615, respectively.
Genefic Pharmacy, Genefic Infusion, Boost, and Pala have a standardized approach to estimate the amount of consideration that we expect to be entitled to for its pharmaceutical revenue, and COVID-19 testing including the impact of contractual allowances (including payer denials), and patient price concessions. The Company principally estimates the allowance for credit losses by pool based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding. Adjustments to our estimated contractual allowances and implicit patient price concessions are recorded in the current period as changes in estimates.
(i) Inventory
Inventory is recorded at the lower of cost or net realizable value on a first-in first-out (“FIFO”) basis. As of June 30, 2024 and 2023, inventory is comprised of raw materials purchased from suppliers, work-in-progress, and finished goods produced or purchased for resale. The Company establishes inventory reserves for estimated obsolete or unsaleable inventory equal to the difference between the cost of inventory and the estimated realizable value based upon assumptions about future market conditions. No reserve was established for as of June 30, 2024 and 2023, respectively.
(j) Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:
Schedule of property and equipment estimated useful life
Estimated Useful Life
Computer and office equipment 3 - 5 years
Machinery and equipment 5 years
Leasehold improvements Shorter of lease term or useful life
Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the Condensed Consolidated Balance Sheet and any resulting gains or losses are included in the Condensed Consolidated Statement of Operations and Comprehensive Loss in the period of disposal.
(k) Business Combinations and Asset Acquisitions
The Company accounts for acquisitions in which it obtains control of one or more businesses as a business combination. The purchase price of the acquired businesses is allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The excess of the purchase price over those fair values is recognized as goodwill. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments, in the period in which they are determined, to the assets acquired and liabilities assumed with the corresponding offset to goodwill. If the assets acquired are not a business, the Company accounts for the transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase.
(l) Contingent Consideration
A Company acquisition includes contingent consideration as part of the purchase price. The fair value of the contingent consideration is estimated as of the acquisition date based on the present value of the contingent payments to be made using a weighted probability of possible payments. The unobservable inputs used in the determination of the fair value of the contingent consideration include managements assumptions about the likelihood of payment based on the established benchmarks and discount rates based on internal rate of return analysis. The fair value measurement includes inputs that are Level 3 measurement as discussed in Note 2. Summary of Significant Accounting Policies of our condensed consolidated financial statements included in this Annual Report on Form 10-K. Should actual results increase or decrease as compared to the assumption used in our analysis, the fair value of the contingent consideration obligations will increase or decrease, up to the contracted limit, as applicable. Changes in the fair value of the contingent earn-out consideration could cause a material impact and volatility in our operating results. The contingent consideration decreased by $4,238,046 to a balance of $47,343 during the year ended June 30, 2024, and the balance was subsequently transferred to a current liability. The outstanding balance of as of June 30, 2024 is in relation to the recognition of contract related contingencies.
(m) Impairment of Long-Lived Assets
The Company reviews its long-lived assets (property and equipment and amortizable intangible assets) for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the expected cash flows, undiscounted, is less than the carrying amount of the asset, an impairment loss is recognized as the amount by which the carrying amount of the asset exceeds its fair value.
Goodwill is tested annually at June 30 for impairment and upon the occurrence of certain events or substantive changes in circumstances.
The annual goodwill impairment test allows for the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. An entity may choose to perform the qualitative assessment on none, some or all of its reporting units or an entity may bypass the qualitative assessment for any reporting unit and proceed directly to step one of the quantitative impairment tests. If it is determined, on the basis of qualitative factors, that the fair value of a reporting unit is, more likely than not, less than its carrying value, the quantitative impairment test is required. The quantitative impairment test calculates any goodwill impairment as the difference between the carrying amount of a reporting unit and its fair value, but not to exceed the carrying amount of goodwill. As of June 30, 2024 and 2023, there were quantitative factors that indicated goodwill was impaired in the amounts of $0 and $433,556, respectively.
An intangible asset is an identifiable non-monetary asset without physical substance. Such an asset is identifiable when it is separable, or when it arises from contractual or other legal rights. Separable assets can be sold, transferred, licensed, etc. Examples of intangible assets include computer software, licenses, trademarks, patents, films, and copyrights. The Company’s intangible assets are finite lived assets and are amortized on a straight-line basis over the estimated useful lives of the assets.
(n) Revenue Recognition
The Company determines revenue recognition in accordance with ASU 2014-09, Revenue from Contracts with Customers, and its related amendments (collectively known as “ASC 606”) through the following steps:
- Identification of a contract with a customer;
- Identification of the performance obligations in the contract;
- Determination of the transaction price;
- Allocation of the transaction price to the performance obligations in the contract; and
- Recognition of revenue when or as the performance obligations are satisfied.
Revenue is recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. As a practical expedient, the Company does not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less.
The Company’s revenue is derived from the sales of its products, which represents net sales recorded in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss. Product sales are recognized when performance obligations under the terms of the contract with the customer are satisfied. Typically, this would occur upon transfer of control, including passage of title to the customer and transfer of risk of loss related to those goods. The Company measures revenue as the amount of consideration to which it expects to be entitled in exchange for transferring goods (transaction price). The Company records reductions to revenue for estimated customer returns, allowances, markdowns, and discounts. The Company bases its estimates on historical rates of customer returns and allowances as well as the specific identification of outstanding returns, markdowns and allowances that have not yet been received by the Company. The actual amount of customer returns and allowances is inherently uncertain and may differ from the Company’s estimates. If the Company determines that actual or expected returns or allowances are significantly higher or lower than the reserves it established, it will record a reduction or increase, as appropriate, to net sales in the period in which it makes such a determination. Reserves for returns and markdowns are included within accrued expenses and other liabilities in the Company’s Condensed Consolidated Balance Sheets. Allowance and discounts are recorded in accounts receivable, net and the value of inventory associated with reserves for sales returns are included within prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.
The Company estimates warranty claims reserves based on historical results and research and determined that a warranty reserve was not necessary as of June 30, 2024, or 2023.
Net revenues from specialty pharmacy accounted for over 61% of the Company’s total net revenues for the year ended June 30, 2024. Sales are recognized at an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring control of goods or services to the customer. The Company recognizes revenue, net of taxes and expected returns, at the time it sells merchandise, provides services or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payors (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts.
The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:
Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.
The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility.
Boost, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered. Pala does not invoice the patients themselves for testing but relies on healthcare insurers and government payers for reimbursement for COVID-19 testing. Boost has a standardized approach to estimate the amount of consideration that we expect to be entitled to, including the impact of contractual allowances (including payer denials), and patient price concessions. We regularly assess the state of our billing operations in order to identify issues which may impact the collectability of receivables or revenue estimates. We believe that the collectability of our receivables is directly linked to the quality of our billing processes, most notably those related to obtaining the correct information in order to bill effectively for the services we provide. As such, we strive to implement “best practices” and work with our third-party billing company to reduce the number of requisitions that we receive from healthcare providers with missing or incorrect billing information. We believe that our collection and revenue estimation processes, along with our close monitoring of our billing operations, help to reduce the risk associated with material adjustments to reserve estimates. However, changes to our estimate of the impact of contractual allowances (including payer denials) and patient price concessions could have a material impact on our results of operations and financial condition in the period that the estimates are adjusted. Adjustments to our estimated contractual allowances and implicit patient price concessions are recorded in the current period as changes in estimates. Although we have limited track record, further adjustments to the allowances, based on actual receipts, may be recorded upon settlement.
DES recognizes revenue on energy savings contracts where it provides design, engineering and equipment upgrades to obtain energy savings through Environmental, Social, and Governance (“ESG”) targets. DES recognizes revenue through two performance obligations: 1) the Energy Savings Report (point in time); and 2) functional IP license (point in time with a significant financing component and royalty and variable consideration constraint). Up to and upon completion of an energy savings project, DES calculates the monthly energy savings based on prior and current energy consumption totals. Upon completion of a project, the customer pays monthly fixed payments which represents a financing component. DES recognized monthly interest income and “royalty” revenue when the constraint from the energy savings percentage is known. DES records revenue as it provides additional management, consulting, and other services as they are incurred.
DES records a sales-type where the Company is the lessor. The Company records its investment in the plant and equipment, used to upgrade a customer’s real property, leased to franchisees on a net basis, which is comprised of the present value of fixed lease payments not yet received over the course of the energy savings agreements. The current and noncurrent portions of our net investment in sales-type leases are included in “Accounts Receivable, net - related parties” and “Noncurrent receivables - related parties” respectively in the Condensed Consolidated Balance Sheets. Unearned income is recognized as interest income over the lease term. Sales-type leases result in the recognition of gain or loss at the commencement of the lease, which is recorded to “Revenues - related party” in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
DepTec and Bothof recognize revenues using a cost-based input method, by which we use actual costs incurred relative to the total estimated contract costs to determine, as a percentage, progress toward contract completion. Provisions for estimated losses on uncompleted contracts are made in the period in which such losses are determined.
The Company also earns service revenue from its other subsidiaries, including information technology and consulting services via Prakat, educational programs, and courses from Dalrada Career Institute, energy services and solutions from Dalrada Technology Spain and Likido, and custom parts manufacturing for Dalrada Precision Parts. For Prakat, Dalrada Precision Parts, Dalrada Technology Spain and Likido, revenues are recognized when performance obligations have been satisfied and the services are complete. This is generally at a point of time upon written completion and client acceptance of the project or product, which represents transfer of control to the customer. For IHG, revenues are recognized over the course of a semester while services are performed.
Disaggregation of Revenue
The following table presents the Company's revenue disaggregated by revenue source:
Schedule of disaggregated revenue
Year Ended
June 30,
Product sales - third parties $ 18,384,320 $ 7,324,522
Product sales - related party 77,308
Service revenue - third parties 5,077,594 20,131,701
Service revenue - related party 1,717,692 2,205,438
Total revenue $ 25,179,746 $ 29,738,969
Accounts Receivable and Deferred Revenue
The following table provides information about receivables and contract liabilities from contracts with customers:
Schedule of receivables and contract liabilities
June 30, June 30,
Accounts receivable, net $ 7,403,933 $ 4,453,104
Accounts receivable, net - related parties 1,236,484 752,348
Noncurrent receivables 20,742 41,722
Noncurrent receivables - related parties 1,136,508 1,173,893
Deferred revenue 452,411 1,337,259
The Company invoices customers based upon contractual billing schedules, and accounts receivable are recorded when the right to consideration becomes unconditional. Contract liabilities represent a set-up fee prepayment received from a customer in advance of performance obligations met. For the fiscal years ended June 30, 2024 and 2023, $993,962 and $242,015 of beginning deferred revenue was recognized as revenue, respectively.
(o) Cost of Revenue
Cost of revenue consists primarily of inventory sold and related freight for product sales and direct labor for information technology and consulting services. The following table is a breakdown of cost of revenue:
Schedule of cost of revenue
Year Ended
June 30
Product sales $ 12,628,731 $ 5,546,015
Service revenue 6,742,179 15,133,035
Total cost of revenue $ 19,370,910 $ 20,679,050
(p) Advertising
Advertising costs are expensed as incurred. During the fiscal years ended June 30, 2024, and 2023, advertising expenses were $185,261 and $292,473, respectively.
(q) Stock-based Compensation
The Company records stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the quoted market price of the equity instruments issued. During the years ended June 30, 2024, and 2023, stock-based compensation expenses were $4,244,096 and $4,022,656, respectively.
(r) Foreign Currency Translation
The functional currency of the Company is the United States dollar. The functional currency of the Likido, DepTec, and Dalrada Technology subsidiaries is the Great British Pound. The functional currency of Prakat is the Indian Rupee. The functional currency of Dalrada Technology Spain is the Euro. The financial statements of the Company’s subsidiaries were translated to United States dollars in accordance with ASC 830, Foreign Currency Translation Matters, using period-end rates of exchange for assets and liabilities, and average rates of exchange for the year for revenues and expenses. Gains and losses arising on foreign currency denominated transactions are included in the Other Comprehensive Loss section of the Condensed Consolidated Statements of Operations and Comprehensive Loss.
(s) Comprehensive Loss
ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the condensed consolidated financial statements. During the years ended June 30, 2024, and 2023, the Company’s only component of comprehensive loss was foreign currency translation adjustments.
(t) Non-controlling Interests
Non-controlling interests are classified as a separate component of equity in the Company's Condensed Consolidated Balance Sheets and Statements of Changes in Stockholders’ Equity. Net loss attributable to non-controlling interests are reflected separately from condensed consolidated net loss in the Condensed Consolidated Statements of Comprehensive Loss and Statements of Changes in Stockholders’ Equity (Deficit). Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests. In addition, when a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary will be initially measured at fair value and the difference between the carrying value and fair value of the retained interest will be recorded as a gain or loss.
As of June 30, 2024, and 2023, non-controlling interests pertained to the Company’s Prakat and Pala subsidiaries in the amount of 25.4%, and 51.0%, respectively.
(u) Basic and Diluted Net Loss per Share
The Company computes net income (loss) per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the periods using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the periods is used in determining the number of shares assumed to be purchased from the exercise of warrants.
There were no adjustments to the numerator during the years ended June 30, 2024 and 2023.
(v) Income Taxes
The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company had a full valuation allowance at June 30, 2024 and 2023, respectively.
(w) Recent Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending June 30, 2025.
3. Investment in Pala Diagnostics
In August 2021, Dalrada entered a joint venture (“JV”) with Vivera Pharmaceuticals, Inc (“Vivera”) for a 51% ownership and controlling interest to operate a CLIA-certified diagnostics lab focused on SARS-CoV-2 testing. The JV has been treated as a business combination.
The Company determined that Pala is a Variable Interest Entity (“VIE”); we believe that the Company has the power to direct the activities that most significantly impact the economic performance of Pala, and accordingly, Dalrada is considered the primary beneficiary of the VIE. The Company has consolidated the activities of the VIE.
Pursuant to the partnership agreement, Dalrada contributed equity in the amount of $500,000 for operating capital and Vivera contributed property and equipment at a fair value of $111,185. This amount was recorded to non-controlling interest equity balance in the Company’s Condensed Consolidated Balance Sheets.
Pursuant to the JV agreement, Dalrada issued 250,000 shares of common stock to Vivera in October 2021. The fair value of $58,560 was recorded to goodwill as of June 30, 2022. This goodwill balance was written down to $0 as of June 30, 2023.
In December 2021, Dalrada Health filed suit against Vivera and Paul Edalat, Vivera’s Chairman and CEO, for misappropriation of funds on behalf of the joint venture in the amount of $2,104,509, accounted for as an unauthorized distribution. In addition to filing a cross-complaint against Dalrada Health Products, Vivera filed a separate complaint against Dalrada Financial Corporation, Empower Genomics, Dalrada Financial Corporation’s officers, and other unrelated parties. See Note 14. Commitments and Contingencies for legal proceedings.
4. Business Combinations and Asset Acquisition
Fiscal 2024 Transactions
IV Services, LLC dba Genefic Infusion Rx
On May 13, 2024, the Company acquired 100% of IV Services, LLC dba Genefic Infusion Rx (“IVS”) through a Membership Interest Purchase Agreement. IVS is a Louisiana based pharmacy that holds pharmacy licenses in Louisiana and Mississippi and specializes in home infusion services. Pursuant to the terms of the transaction, the Company acquired all assets, tangible and intangible, which relate to, or are used or held for use in connection with the business for cash, closing date inventory, closing date rent payment, closing date cash on hand, and total liabilities of $156,926.
The Company acquired IVS to expand the physical footprint of Genefic Specialty Rx as well as its ability to ship a larger volume of prescriptions and to enter the infusion pharmacy business.
The IVS transaction was accounted for as a business combination in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC 805”). The Company has determined preliminary fair values of the assets acquired and liabilities assumed. These values are subject to change as we perform additional reviews of our assumptions utilized.
The Company has made a preliminary allocation of the purchase price regarding the acquisition related to the assets acquired and liabilities assumed as of the purchase date. The following table summarizes the purchase price allocation as of May 13, 2024:
Schedule of purchase price allocation
Preliminary
Purchase Price Allocation
Cash and cash equivalents $ 2,991
Inventory 149,216
Prepaid expenses 2,390
Deposits 10,700
Fixed assets, net 166,526
IP-technology-license 99,000
Non-competes 17,500
Goodwill 371,298
Accounts payable (97,494 )
Accrued compensation - PTO (12,933 )
Loan payable (46,500 )
Purchase price consideration $ 662,694
Fiscal 2023 Transactions
Bothof Brothers Construction Inc.
On October 17, 2022, the Company acquired 100% of the common stock of Bothof Brothers Construction Inc. (“Bothof”). The Company assumed the net liabilities of the Bothof in exchange for the employment services of the selling shareholder. All considerations in the transaction required the continued employment of the selling shareholder and thus is not consideration transferred under ASC 805.
The Company entered into a 36-month employment agreement with the selling shareholder for $30,000 monthly and additionally issued 3,000,000 cashless warrants, at a strike price of $0.15 per share, to equal $450,000, which vest quarterly over a period of 24 months (the “Warrant Consideration”).
If at the end of the 24-month warrant distribution period, beginning on the effective date of October 17, 2022 (the “Distribution Period”), the value of cashless warrants does not equate to $6,000,000 (the “Target Amount”) in value, then the Company shall issue additional cashless warrants equal to the shortfall between the value of the Warrants Consideration and the Target Amount (the “Valuation Shortfall”).
The value of the Warrant Consideration to the selling shareholder is $3,482,550. The Company records the value as stock-based compensation on a straight-line basis over the vesting period of 24-months.
The Warrant Consideration is contingent on the selling shareholder’s continued employment with the Company; therefore, it is treated as stock-based compensation expense and recognized ratably over a 24-month period.
The Company acquired Bothof to facilitate the work of and expand the Dalrada Energy Services segment. Bothof’s selling shareholder holds certain licenses, construction/engineering design expertise and management skills which will leverage synergies with Dalrada Energy Services.
The Bothof transaction was accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed.
The Company has made a preliminary allocation of the purchase price regarding the acquisition related to the assets acquired and liabilities assumed as of the purchase date. The following table summarizes the purchase price allocation as of October 17, 2022:
Schedule of purchase price allocation
Preliminary
Purchase Price Allocation
Cash and cash equivalents $ 70,979
Other receivables 27,289
Right of use asset, net 18,618
Property and equipment, net 17,179
Trade name 6,776
Accounts payable (24,165 )
Accrued liabilities (18,807 )
Deferred revenue (60,000 )
Lease liability (18,618 )
Notes payable, current portion (19,251 )
Purchase price consideration $ -
Trade name is amortized on a straight-line basis over one month. The fair value estimate of the trade name for the purchase price allocation was based on an analysis of the present value of future cash flows and relief from royalty method.
Dalrada Technology LTD EU (“DTL”)
On March 1, 2023, the Company acquired 100% of the common stock of DTL in an asset acquisition. In consideration for the asset acquisition, the Company issued 1,000,000 cashless warrants, at a strike price of $0.10 per share, which shall vest quarterly over 36 months.
The value of the Warrant Consideration to the selling shareholder is $68,975. The value was calculated using the Black-Scholes model. The Company recorded a liability for the warrants at the acquisition date as the warrants are not contingent on employment of the sellers.
The Company acquired DTL as a holding company for its European operations, including Likido Ltd. and DepTec. DTL will also be utilized to pursue certain European grants and other governmental funding opportunities. The two sellers of DTL are related parties to the Chairman and CEO of the Company.
The DTL transaction was accounted for as an asset acquisition in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed.
The Company has made a preliminary allocation of the purchase price regarding the asset acquisition related to the assets acquired and liabilities assumed as of the purchase date. The following table summarizes the purchase price allocation as of March 1, 2023:
Schedule of purchase price allocation
Preliminary
Purchase Price Allocation
Cash and cash equivalents $ 9,108
Deposits 13,536
Prepaids 24,666
Furniture and Fixtures 64,533
Trade name 206,336
Loan Payable (249,204 )
Purchase price consideration $ 68,975
Trade name is amortized on a straight-line basis over two years.
5. Selected Balance Sheet Elements
Inventories
Inventories consisted of the following as of June 30, 2024, and 2023:
Schedule of inventories
June 30, June 30,
Raw materials $ 910,679 $ 658,175
Work-in-progress 1,129,348 708,007
Finished goods 607,625 712,510
Inventories $ 2,647,652 $ 2,078,692
Property and Equipment, Net
Property and equipment, net consisted of the following as of June 30, 2024, and 2023:
Schedule of property and equipment
June 30, June 30,
Machinery and equipment $ 1,769,470 $ 1,448,556
Leasehold improvements 416,854 208,689
Computer and office equipment 458,689 426,162
Construction in progress - 249,613
Property and equipment, gross 2,645,013 2,333,020
Less: Accumulated depreciation (1,192,731 ) (856,938 )
Property and equipment, net $ 1,452,282 $ 1,476,082
Depreciation expense of $473,183 and $360,544 for the years ended June 30, 2024, and 2023, respectively, were included in selling, general and administrative expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
Goodwill
Goodwill consisted of the following by entity as of June 30, 2024, and 2023:
Schedule of goodwill
Precision Genefic Total
Balance: June 30, 2023 $ 3,106,090 $ 697,057 $ 3,803,147
Additions - 372,611 372,611
Balance: June 30, 2024 $ 3,106,090 $ 1,069,668 $ 4,175,758
Precision Genefic Total
Balance: June 30, 2022 $ 3,122,811 $ 1,130,613 $ 4,253,424
Additions - - -
Adjustments to purchase price allocation (16,721 ) - (16,721 )
Less: loss on impairment - (433,556 ) (433,556 )
Balance: June 30, 2023 $ 3,106,090 $ 697,057 $ 3,803,147
Intangible Assets, Net
Intangible assets, net consisted of the following as of June 30, 2024, and June 30, 2023:
Schedule of intangible assets, net
Developed
technology,
Curriculum
Customer
software,
development Licenses relationships Trademarks and other Totals
Balance: June 30, 2023 $ 693,385 $ 1,064,000 $ 1,244,480 $ 535,547 $ 813,479 $ 4,350,891
Additions - - - - 116,500 116,500
Balance: June 30, 2024 693,385 1,064,000 1,244,480 535,547 929,979 4,467,391
Less: Accumulated amortization
Balance: June 30, 2023 (172,230 ) (55,378 ) (153,770 ) (54,595 ) (56,832 ) (492,805 )
Additions (69,339 ) (51,118 ) (124,448 ) (116,324 ) (66,091 ) (427,320 )
Balance: June 30, 2024 (241,569 ) (106,496 ) (278,218 ) (170,919 ) (122,923 ) (920,125 )
Net book value: June 30, 2024 $ 451,816 $ 957,504 $ 966,262 $ 364,628 $ 807,056 $ 3,547,266
Developed
technology,
Curriculum
Customer
software,
development Licenses relationships Trademarks and other Totals
Balance: June 30, 2022 $ 693,385 $ 1,064,000 $ 1,230,159 $ 348,100 $ 335,021 $ 3,670,665
Additions - - - 186,047 477,458 663,505
Adjustments to purchase price allocation - - 14,321 1,400 1,000 16,721
Balance: June 30, 2023 693,385 1,064,000 1,244,480 535,547 813,479 4,350,891
Less: Accumulated amortization
Balance: June 30, 2022 (102,891 ) (4,260 ) (30,754 ) (380 ) (7,492 ) (145,777 )
Additions (69,339 ) (51,118 ) (123,016 ) (54,215 ) (49,340 ) (347,028 )
Balance: June 30, 2023 (172,230 ) (55,378 ) (153,770 ) (54,595 ) (56,832 ) (492,805 )
Net book value: June 30, 2023 $ 521,155 $ 1,008,622 $ 1,090,710 $ 480,952 $ 756,647 $ 3,858,086
Amortization expense of $426,220 and $347,028 for the years ended June 30, 2024, and 2023, respectively, were included in selling, general and administrative expenses in the statements of operations and comprehensive loss. The Company’s intangible assets are subject to amortization and are amortized over the straight-line methods over their estimated period of benefit.
Future amortization expense is as follows:
Schedule of future amortization expense
Year Ending June 30,
$ 416,132
338,891
338,891
338,891
332,358
Thereafter 1,782,102
Total $ 3,547,266
6. Accrued Payroll Taxes
As of June 30, 2024, and 2023, the Company had $0 and $0, respectively, of accrued payroll taxes, penalties and interest relating to calendar years 2004 - 2007. The total balance for accrued payroll taxes accumulated on a quarterly basis beginning on their respective quarterly filing dates. Accrued interest was compounded daily at an estimated effective interest rate of 7.33%. The quarterly sub-totals that made up the balance had a calculated expiration date of 10 years according to the Internal Revenue Service statute of limitations. As the tax periods surpassed their estimated expiration date, the Company removed the liability from the Condensed Consolidated Balance Sheets, and an equivalent amount was recognized as “Gain on expiration of accrued tax liability” within other income on the Condensed Consolidated Statements of Operations and Comprehensive Loss. For the years ended June 30, 2024, and 2023, the Company recognized $0 and $35,242, respectively, of penalties and interest within interest expense on the Condensed Consolidated Statements of Operations and Comprehensive Loss. For the years ended June 30, 2024, and 2023, the Company recognized $0 and $2,090,978, respectively, within “Gain on expiration of accrued tax liability” related to quarterly tax liabilities that expired during the respective fiscal years.
7. Notes Payable
Notes Payable - Related Parties
The following is a summary of notes payable - related parties as of June 30, 2024, and 2023:
Schedule of notes payable - related parties
June 30, 2024
Outstanding Accrued
Principal Interest
Related entity 1 $ - $ -
Related entity 2 52,887 -
Related entity 3 - -
Related entity 4 1,070 -
Related entity 5 - -
Related entity 6 - -
$ 53,957 $ -
June 30, 2023
Outstanding Accrued
Principal Interest
Related entity 1 $ 1,380,672 $ 3,038
Related entity 2 126,864 -
Related entity 3 105,000 -
Related entity 4 50,074 -
Related entity 5 - -
Related entity 6 237,473 11,144
$ 1,900,083 $ 14,182
The following is a summary of current and noncurrent notes payable - related parties as of June 30, 2024, and 2023:
Schedule of current and noncurrent notes payable - related parties
June 30, 2024
Current Long-Term
Portion Portion Total
Related entity 1 $ - $ - $ -
Related entity 2 - 52,887 52,887
Related entity 3 - - -
Related entity 4 - 1,070 1,070
Related entity 5 - - -
Related entity 6 - - -
$ - $ 53,957 $ 53,957
June 30, 2023
Current Long-Term
Portion Portion Total
Related entity 1 $ - $ 1,380,672 $ 1,380,672
Related entity 2 - 126,864 126,864
Related entity 3 - 105,000 105,000
Related entity 4 14,132 35,942 50,074
Related entity 5 - - -
Related entity 6 237,473 - 237,473
$ 251,605 $ 1,648,478 $ 1,900,083
All notes dated December 31, 2022, and prior are unsecured, bear interest at 3% per annum, and are due 360 days from the date of issuance, ranging from June 25, 2020, to December 30, 2022. All notes dated after December 31, 2022, are unsecured, bear interest at 8% per annum, and are due 1095 days from the date of issuance. Each related party has significant influence or common ownership with the Company’s Chief Executive Officer. Several of these notes are in default. The Company has not received any notices of default or demands for payment. All notes are unsecured and those which are past-due are due on demand. As of June 30, 2024 and 2023, total accrued interest for Notes Payable-Related Parties was $0 and $14,182, respectively. The Company recorded interest expense from Notes Payable-Related Party for fiscal years ending June 30, 2024, and 2023, of $244,750 and $814,240, respectively.
There were various related party debt convertible notes that occurred during 2024 and 2023 (see “Note 8. Convertible Note Payable - Related Parties” for more information).
The following are the expected future payments as of June 30, 2024:
Schedule of expected payments - related parties
Fiscal Year Ended June 30,
$ -
53,957
-
-
-
Total $ 53,957
Notes Payable
Notes payable includes the following:
Schedule of note payable
June 30, June 30,
Current portion $ 4,468,760 $ 439,562
Noncurrent portion 2,332,003 1,011,395
Total $ 6,800,763 $ 1,450,957
The Company’s Economic Injury Disaster Loan (“EIDL”) dated May 10, 2020, include a 3.75% interest rate for up to 30 years; the payments are deferred for the first two years (during which interest will accrue), and payments of principal and interest are made over the remaining 28 years. The EIDL loan has no penalty for prepayment. The EIDL loan attaches collateral which includes the following property that EIDL borrower owns or shall acquire or create immediately upon the acquisition or creation thereof: all tangible and intangible personal property, including, but not limited to: (a) inventory, (b) equipment, (c) instruments, including promissory notes (d) chattel paper, including tangible chattel paper and electronic chattel paper, (e) documents, (f) letter of credit rights, (g) accounts, including health-care insurance receivables and credit card receivables, (h) deposit accounts, (i) commercial tort claims, (j) general intangibles, including payment intangibles and software and (k) as-extracted collateral as such terms may from time to time be defined in the Uniform Commercial Code. The security interest the EIDL borrower grants includes all accessions, attachments, accessories, parts, supplies and replacements for the collateral, all products, proceeds and collections thereof and all records and data relating thereto. The balance of IHG’s EIDL is $150,000 and $147,807 for the years ended June 30, 2024, and 2023, respectively. The EIDL loan is technically in default as a result of a change in ownership without the Small Business Administration (“SBA”) prior written consent. The Company has contacted the SBA regarding the transfer of ownership and has not yet finalized the transfer of ownership.
The Company’s COVID-19 Government Loan includes a 2.5% interest rate for up to six years; the payments are deferred for the first year (during which interest will accrue). The balance of COVID-19 Government Loan is $24,206 and $36,938 for the years ended June 30, 2024, and 2023, respectively.
The Company has a loan totaling $95,060 and $320,709 as of June 30, 2024, and 2023, respectively, which includes an interest rate of 5% with a maturity date of April 29, 2025. The loan is collateralized by personal property and includes monthly payments in the amount of $2,656, with a balloon payment at the maturity date in the amount of $336,898. The Company renewed a loan on June 26, 2023, for $176,836, which includes an interest rate equal to the Wall Street Journal Prime Rate, or 8.25% as of June 30, 2023, and a maturity date of June 26, 2024. The loan is collateralized by the accounts receivable of the Company and includes four payments of $46,838.
On July 25, 2023, the Company entered into an agreement with OnPoint LTB, LLC, for a credit line and funding of up to $2,000,000. The terms of the credit line include a 24-month term loan, with interest only for 6 months, then amortizing over 18 months down to 50%, with the remaining 50% of the balance due at the end of term. Interest is fixed at 20% per annum, with an origination fee of $20,000 which is added to the loan balance. The Company borrowed the first installment of $1,200,000 at the time of closing and the remaining $800,000 was borrowed on October 4, 2023. As part of the loan origination fee, the Company issued 500,000 shares of its common stock. The transaction includes a debt discount of $189,971 which is amortized using an effective interest method over a 24-month period. The net balance of the loan is $1,561,395 as of June 30, 2024.
On January 4, 2024, the Company executed a revenue purchase agreement with NewCo Capital Group LLC for $350,000, which includes a 17% purchase percentage and a total purchased amount of $507,500 at the end of the term. The agreement includes a $10,500 underwriting fee and a $10,500 origination fee.
On January 22, February 22, a loan and security agreement was executed with Nautilus Parent Holding, LLC whereby the Company can borrow 80% of the estimated accounts receivable at 2% interest per month for up to a maximum draw down of $750,000. On April 18, 2024, the Company board of directors approved to increase the maximum draw down to $8,000,000. As of June 30, 2024, the total drawdown was $2,900,000. The agreement includes a $5,000 expense deposit.
On April 8, 2024, the Company entered into a promissory note with 1800 Diagonal Lending, LLC for $172,500. The promissory note includes a one-time interest charge of 14%, which was applied on the issuance date, and matures on February 15, 2025. There are 10 monthly payments in the amount of $19,665 for a total payback of $196,650. In the event of default, 1800 Diagonal Lending, LLC shall have the right to convert all or part of the outstanding and unpaid amount of the note into common shares equal to 61% multiplied by the lowest trading price of the Company common stock during the 10 trading days prior to the conversion date.
On May 2, 2024, the Company executed a revenue purchase agreement with Credit Line Capital Group for $600,000, which includes a 14% purchase percentage and a total purchased amount of $786,000 at the end of the term. The agreement includes a $6,000 underwriting fee and a $6,000 origination fee.
On May 16, 2024, the Company entered into a promissory note with 1800 Diagonal Lending, LLC for $122,475. The promissory note includes a one-time interest charge of 14%, which was applied on the issuance date, and matures on March 30, 2025. There are 10 monthly payments in the amount of $13,962 for a total payback of $139,621. In the event of default, 1800 Diagonal Lending, LLC shall have the right to convert all or part of the outstanding and unpaid amount of the note into common shares equal to 61% multiplied by the lowest trading price of the Company common stock during the 10 trading days prior to the conversion date.
On May 16, 2024, the Company entered into a term loan with Agile Capital Funding, LLC for $525,000 and includes an administrative fee in the amount of $23,625. There are 32 weekly payments in the amount of $22,641 for a total payback of $724,500.
On June 25, 2024, the Company executed a revenue purchase agreement with Cucumber Capital LLC for $325,000, which includes a 9% purchase percentage and a total purchased amount of $487,175 at the end of the term. The agreement includes a $19,500 origination fee.
The following are the expected future payments as of June 30, 2024:
Schedule of expected future payments
Fiscal Year Ending June 30,
$ 4,468,760
2,167,053
19,902
23,068
17,222
Thereafter 104,759
Total $ 6,800,763
8. Convertible Note Payable - Related Parties
On February 1, 2022, $6,532,206 of related party debt principal and interest related to promissory notes issued by the Company, with the option for conversion, was converted into 10,002 shares of Series G Convertible Preferred Stock (“Series G Stock”). The Series G Stock shall convert at one share of Series G Stock to 2,177 shares of common stock (equivalent to converting the related dollars into common shares at $0.30 per share).
On April 4, 2023, $4,544,224 of related party debt principal and interest related to promissory notes issued by the Company, with the option for conversion, was converted into 15,002 shares of Series H Convertible Preferred Stock (“Series H Stock”). The Series H Stock shall convert at one share of Series H Stock to 3,029 shares of common stock (equivalent to converting the related dollars into common shares at $0.10 per share).
On June 23, 2023, $29,315,320 of related party debt principal and interest related to promissory notes issued by the Company, with the option for conversion, was converted into 35,108 shares of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share).
On March 29, 2024, $13,318,783 of related party debt principal and interest related to promissory notes issued by the Company, with the option for conversion, was converted into 15,951 shares of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share).
Pursuant to the acquisition agreement dated April 6, 2022, between the Company and Silicon Services Consortium Ltd. (“SSCe”), the sellers of SSCe were to be issued 3,000,000 shares of its common stock evenly every quarter for 24 months with the initial distribution to take place on the effective date (the “Share Consideration”). If at the end of the 24-month stock distribution period, beginning on the effective date of April 7, 2022 (the “Distribution Period”), the value of common stock consideration does not equate to 4,000,000 GBP (the “Target Amount”) in value, then the Company shall issue additional stock equal to the shortfall between the value of the Share Consideration and the Target Amount (the “Valuation Shortfall”). At the end of the Distribution Period, the sellers of SSCe were to be issued an additional $4,440,000 in stock as a result of the Valuation Shortfall. The Company share price at the end of the Distribution Period was $0.20, creating an additional 22,200,000 shares of common stock due to the sellers of SSCe. Pursuant to board resolution dated May 22, 2024, Valuation Shortfall shares were issued into 4,440 shares of Series I Convertible Preferred Stock (“Series I Stock”) as opposed to common stock. The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights.
On June 30, 2024, the Company converted $3,924,499 of related party debt principal and interest into 4,700 shares of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights.
9. Related Party Transactions
Fiscal 2024 Transactions
During the year ended June 30, 2024, the Company received cash funding or expenses paid on behalf of the Company from related parties totaling $2,923,418. The expenses paid on their behalf primarily relate to operational expenditure and payroll. In most cases, promissory notes were created on a quarterly basis totaling the amounts referenced above. The remaining amounts are included within accounts payable - related parties for which the related parties expect repayment. The above-referenced expenses relate to three corporations that the Company has classified as related parties. These corporations are all owned and/or operated by an individual who has a familial relationship with the Company’s CEO.
As of June 30, 2024, amounts included within accounts payable and accrued liabilities - related parties for related party expenses were $136,976.
Fiscal 2023 Transactions
During the year ended June 30, 2023, the Company received cash funding or expenses paid on its behalf from related parties totaling $5,439,249. The expenses paid on their behalf primarily relate to operational expenditure and payroll. In most cases, promissory notes were created on a quarterly basis totaling the amounts referenced above. The remaining amounts are included within accounts payable - related parties on the Company’s Condensed Consolidated Balance Sheet for which the related parties expect repayment. The above-referenced expenses relate to three corporations that the Company has classified as related parties. These corporations are all owned and/or operated by an individual who has a familial relationship with the Company’s CEO.
During the year ended June 30, 2023, the Company incurred expenses for services provided by related parties totaling $5,312,020. Services provided to the Company include management services, payroll processing services, rent and chartered flight services. The corporations are either owned and/or operated by a relative of the Company’s CEO, is a corporation in which the Company’s CEO can exercise control or is an individual who has a familial relationship with the Company’s CEO.
During the year ended June 30, 2023, the Company’s Bothof Brothers subsidiary recognized revenue for construction services totaling $2,134,470 from corporations owned and/or operated by a related party who has a familial relationship with the Company’s CEO.
During the year ended June 30, 2023, the Company’s DES subsidiary recognized monthly interest income and royalty revenue totaling $45,968 from corporations owned and/or operated by a related party who has a familial relationship with the Company’s CEO.
During the year ended June 30, 2023, the Company incurred $1,669,788 in services performed by non-employee board members.
As of June 30, 2023, amounts included within accounts payable and accrued liabilities - related parties on the Company’s Condensed Consolidated Balance Sheet for related party expenses were $500,288.
The following is a summary of revenues recorded by the Company’s to related parties with common ownership:
Schedule of revenues
Year Ended
June 30,
Dalrada Health $ - $ 76,912
Dalrada Energy Services 5,207 45,968
Ignite
Prakat 15,000 25,000
Bothof Brothers 1,697,485 2,134,470
$ 1,717,832 $ 2,282,746
See Notes 7, 8, 9, 10, and 14 for additional related party transactions.
10. Preferred Stock
On March 29, 2024, the Company converted $13,318,943 of related party debt principal and interest into 15,951 shares (effective price of $835 per share) of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 3(a)(9) of the Act in that such issuance did not constitute a public offering.
Pursuant to the acquisition agreement dated April 6, 2022 between the Company and Silicon Services Consortium Ltd. (“SSCe”), the sellers of SSCe were to be issued 3,000,000 shares of its common stock evenly every quarter for 24 months with the initial distribution to take place on the effective date (the “Share Consideration”). If at the end of the 24-month stock distribution period, beginning on the effective date of April 7, 2022 (the “Distribution Period”), the value of common stock consideration does not equate to 4,000,000 GBP (the “Target Amount”) in value, then the Company shall issue additional stock equal to the shortfall between the value of the Share Consideration and the Target Amount (the “Valuation Shortfall”). At the end of the Distribution Period, the sellers of SSCe were to be issued an additional $4,440,000 in stock as a result of the Valuation Shortfall. The Company share price at the end of the Distribution Period was $0.20, creating an additional 22,200,000 shares of common stock due to the sellers of SSCe. Pursuant to board resolution dated May 22, 2024, Valuation Shortfall shares were issued into 4,440 shares of Series I Convertible Preferred Stock (“Series I Stock”) as opposed to common stock. The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
On June 30, 2024, the Company converted $3,924,499 of related party debt principal and interest into 4,700 shares (effective price of $835 per share) of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 3(a)(9) of the Act in that such issuance did not constitute a public offering.
11. Stockholders’ Equity
Common Stock Transactions - Fiscal 2024
In July 2023, the Company issued 500,000 shares of common stock in connection with a fee for a third-party loan in the amount of 1,200,000. The company ascribed $60,000 to those shares recorded as a debt discount. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In July 2023, the Company issued 109,637 shares of common stock pursuant to the Stock Purchase Agreement with Prakat Solutions Inc. for $14,413. This issuance was a follow on with certain legacy stockholders of Prakat to the 2020 purchase by the Company of 72% of Prakat. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In September and December 2023, April and May 2024, the Company issued a total of 500,000 shares of common stock related to earn-out payments in the acquisition of Genefic Specialty Pharmacy. The company ascribed $106,250 to those shares recorded at the value of the shares upon issuance. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In October 2023 the company issued 500,000 shares of common stock pursuant to a loan agreement for $173,000. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In December 2023 and April 2024, the Company issued a total of 1,000,002 shares of common stock related to the acquisition of DepTec (SSCe) for $200,947. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
In February 2024, the Company issued 4,666,665 shares of common stock related to a Company conducted private placement for aggregate proceeds of $604,001, or $0.13 per share. The Company used the proceeds for operating capital. The Company issued these shares of common stock pursuant to the exemption from registration abiding by Rule 506 under Regulation D.
In February 2024, the Company issued 1,200,000 shares of common stock pursuant to consulting agreements resulting in $241,200 in consultancy fees. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.
12. Stock-Based Compensation
Dalrada Financial Corporation 2020 Stock Compensation Plan
On July 9, 2020, the Board authorized the Dalrada Financial Corporation 2020 Stock Compensation Plan (the “Plan”) to be used to compensate the company’s board of directors. The Plan allocates the issuance of up to 3,500,000 shares. On February 25, 2021, the Company amended the Plan to issue up to 4,500,000 shares and issued an aggregate of 4,500,000 common shares, or 500,000 shares to each board member. Condensed Consolidated Statements of Operations and Comprehensive Loss. On November 10, 2021, the Company cancelled 6,500,000 shares issued under the Plan to the Board of Directors and issued 6,500,000 cashless warrants. A total of 4,500,000 cashless warrants were to vest immediately, and the remaining 2,000,000 cashless warrants were to vest over a 12-month period. All cashless warrants carry a $0.45 exercise price and a ten-year term. The Company recorded stock-based compensation of $730,000 related to the 6,500,000 shares. The issuance of the warrants was treated as a modification and, as a result of the value of the stock-based compensation of the shares cancelled being greater than the stock-based compensation related to the cashless warrants issued, no additional stock-based compensation expense was recorded for the year ended June 30, 2022.
On November 30, 2021, the Company issued 2,275,000 cashless warrants to employees and consultants for services performed. A total of 825,000 cashless warrants were vested immediately and the remaining 1,450,000 cashless warrants vests over a 36-month period. The cashless warrants include an exercise price of $0.45 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.73 per share, or $1,651,093 which was calculated using the Black-Scholes model.
On February 16, 2022, the Company issued 2,250,000 cashless warrants to new members of the Board of Directors. The cashless warrants vest over a 12-month period and hold an exercise price of $0.45 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.59 per share, or $1,338,644, which was calculated using the Black-Scholes model.
On August 11, 2022, the Company issued 2,200,000 cashless warrants to new members of the Board of Directors and Advisors. A total of 1,500,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.45 per share. 450,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.41 per share, and the remaining 250,000 cashless warrants vest over a 12-month period beginning April 8, 2023, and hold an exercise price of $0.45 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.18 per share, or $397,890, which was calculated using the Black-Scholes model.
On October 7, 2022, the Company issued 3,000,000 cashless warrants to the selling shareholder of Bothof in connection with the acquisition of Bothof. The warrants vest over a 24-month period and hold an exercise price of $0.15 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $1.26 per share, or $5,101,223, which was calculated using the Fair Value method. The cashless warrants are contingent on the selling shareholder’s continued employment with the Company; therefore, it is treated as stock-based compensation expense and recognized ratably over a 24-month period.
On March 1, 2023, the Company issued 1,000,000 cashless warrants to the selling shareholders of Dalrada Technology Ltd with the acquisition of Dalrada Technology Ltd. The warrants vest over a 36-month period and hold an exercise price of $0.10 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.07 per share, or $68,975, which was calculated using the Fair Value method.
On April 14, 2023, the Company authorized and issued 26,638,500 cashless warrants to various officers, employees, and consultants of the Company. A total of 5,575,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.45 per share. A total of 3,600,000 cashless warrants vest over a 24-month period and hold an exercise price of $0.45 per share. A total of 5,000,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.33 per share. A total of 1,300,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.20 per share. A total of 500,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.12 per share. A total of 250,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.45 per share. A total of 20,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.09 per share. A total of 6,200,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.16 per share. A total of 2,250,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.25 per share. A total of 1,143,500 cashless warrants vest over a 36-month period and hold an exercise price of $0.08 per share. The remaining 800,000 cashless warrants vest over a 24-month period and hold an exercise price of $0.14 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.08 per share, or $2,143,402, which was calculated using the Black-Scholes model.
On May 25, 2023, the Company authorized and issued 587,634 cashless warrants to various employees of the Company. A total of 537,634 cashless warrants vest over a 36-month period and hold an exercise price of $0.45 per share, and the remaining 50,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.08 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.10 per share, or $47,408, which was calculated using the Black-Scholes model.
On September 6, 2023, the Company authorized and issued 15,861,000 cashless warrants to various officers, employees, and consultants of the Company. A total of 6,000,000 cashless warrants vest over a 24-month period and hold an exercise price of $0.10 per share. A total of 4,200,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.12 per share. A total of 5,161,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.17 per share. A total of 500,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.12 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.08 per share, or $2,064,699, which was calculated using the Black-Scholes model.
On December 14, 2023, the Company authorized and issued 250,000 cashless warrants to various employees of the Company. All 250,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.17 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.17 per share, or $42,056, which was calculated using the Black-Scholes model.
On January 30, 2024, the Company authorized and issued 5,455,000 cashless warrants to various employees and consultants of the company. A total of 3,250,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.20 per share. A total of 1,875,000 cashless warrants vest over a 36-month period and hold an exercise price of $0.12 per share. A total of 80,000 cashless warrants vest over a 30-month period and hold an exercise price of $0.20 per share. A total of 250,000 cashless warrants vest over a 12-month period and hold an exercise price of $0.20 per share.
Schedule of warrants outstanding
Weighted
Common
Weighted
Average
Stock
Average
Remaining
Warrants
Exercise Price
Contractual Life
Outstanding - June 30, 2022
12,025,000
$ -
8.82
Granted
33,426,134
$ 0.29
Exercised
-
-
Forfeited
-
-
Outstanding - June 30, 2023
45,451,134
$ 0.33
8.83
Granted
21,566,000
$ 0.14
Exercised
-
-
Forfeited
(12,840,673)
-
Outstanding - June 30, 2024
54,176,461
$ 0.26
8.28
Exercisable at June 30, 2024
35,986,922
$ 0.31
7.90
Schedule of assumptions
Years Ended June 30,
Risk-free interest rate 4.00% 3.61%
Expected volatility (1) 109.7% 158.3%
Expected dividend yield 0.00% 0.00%
Expected life (years) 5.26 5.27
The intrinsic value of outstanding warrants was $0 as of June 30, 2024, and 2023.
During the year ended June 30, 2024, and 2023, stock-based compensation expenses were $4,244,097 and $4,022,656, respectively. Total unrecognized compensation cost of non-vested options was $2,924,625 and $4,985,051 on June 30, 2024, and 2023, respectively, which will be recognized over the next two and half fiscal years.
13. Segment Reporting
The Company manages its business and makes its decisions within its operating segments. The Company classifies its operations into five segments: Genefic, Climate Technology, Manufacturing, Technology, and Corporate. The Company evaluates the performance of its segments primarily based on revenues and operating income (loss).
Segment information for the years ended June 30, 2024, and 2023 is as follows:
Schedule of segment information
Year Ended June 30, 2024
Genefic Dalrada Climate Technology Dalrada Precision Manufacturing Dalrada Technologies Corporate Consolidated
Revenues $ 17,684,765 $ 3,674,697 $ 2,447,148 $ 1,373,136 $ - $ 25,179,746
Income (Loss) from Operations (1,825,270 ) (5,956,460 ) (1,349,321 ) (235,104 ) (11,409,690 ) (20,775,845 )
Year Ended June 30, 2023
Genefic Dalrada Energy Dalrada Precision Manufacturing Dalrada Technologies Corporate Consolidated
Revenues $ 15,740,919 $ 7,075,414 $ 4,873,225 $ 2,049,411 $ - $ 29,738,969
Income (Loss) from Operations (5,783,441 ) (1,065,221 ) (2,461,219 ) 10,634 (11,660,710 ) (20,959,957 )
Geographic Information
The following table presents revenue by country:
Schedule of revenue by country
Year Ended,
June 30,
United States $ 22,532,068 $ 26,208,432
Scotland 1,242,642 1,887,061
Spain 310,568 -
India 1,094,468 1,643,476
$ 25,179,746 $ 29,738,969
The following table presents inventories by country:
Schedule of inventories by country
June 30, June 30,
United States $ 544,334 $ 584,330
Scotland 2,103,318 1,494,362
$ 2,647,652 $ 2,078,692
The following table presents property and equipment, net, by country:
Schedule of property and equipment by country
June 30, June 30,
United States $ 1,277,282 $ 1,284,834
Scotland 121,180 182,657
Spain 48,121 -
India 5,699 8,591
$ 1,452,282 $ 1,476,082
14. Commitments and Contingencies
Lease Commitments
The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components is recognized when the obligation is probable.
Operating lease right of use (“ROU”) assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real estate) which are classified as operating leases. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company's leases, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.
The lease term for all the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company's leases as the reasonably certain threshold is not met.
Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of the Company option to purchase the underlying asset if reasonably certain.
Variable lease payments not dependent on a rate or index associated with the Company's leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed as probable. Variable lease payments are presented as operating expenses in the Company's Condensed Consolidated Statement of Operations and Comprehensive Loss in the same line item as expense arising from fixed lease payments. As of and during the year ended June 30, 2021, management determined that there were no variable lease costs.
Right of Use Asset
In July 2022, the Company entered into a five-year lease agreement to lease a commercial building in Escondido, California. The building is owned by a related party. The Company recognized a right of use asset and lease liability of $2,405,540 and used an effective borrowing rate of 3.0% within the calculation. Imputed interest is $192,521. The lease agreements mature in June 2027.
In April 2023, the Company’s Prakat subsidiary entered into a lease agreement to lease office space through March 2026. The Company recognized a right of use asset and liability of $99,060 and used an effective borrowing rate of 8% within the calculation.
In May 2021, the Company’s PSC subsidiary entered into a three-year and 6-month lease agreement to lease a medical office space in Poway, California. The Company recognized a right of use asset and lease liability of $277,856 and used an effective borrowing rate of 3.0% within the calculation.
In January 2022, the Company’s IHG subsidiary entered into a five-year and 5-month lease agreement to lease a medical office space in Chula Vista, California. The Company recognized a right of use asset and lease liability of $287,345 and used an effective borrowing rate of 3.0% within the calculation.
In May 2022, the Company’s IHG subsidiary entered into a six-year and 3-month lease agreement to lease an office space in San Diego, California. The Company recognized a right of use asset and lease liability of $919,722 and used an effective borrowing rate of 4.0% within the calculation.
In August 2020, the Company’s DepTec subsidiary entered into a five-year lease agreement to lease office space. The Company recognized a right of use asset and lease liability of $146,622 and used an effective borrowing rate of 3.0%
In May 2021, the Company’s Genefic Specialty Pharmacy subsidiary entered into a three-year lease agreement to lease a building in Florence, Alabama. The Company recognized a right of use asset and lease liability of $90,827 and used an effective borrowing rate of 3.0%
In July 2022, the Company’s Empower subsidiary entered into a five-year lease agreement to lease a commercial space in Escondido, California. The building is owned by a related party. The Company recognized a right-of-use asset and lease liability of $322,756 and used an effective borrowing rate of 3.0% within the calculation. Imputed interest is $25,838. The lease agreement matures in June 2027.
In October 2022, the Company’s Pala Diagnostics entered into a one-year lease agreement to lease a research and development laboratory space in San Diego, California. The Company recognized a right-of-use asset and lease liability of $37,239 And used an effective borrowing rate of 8% within the calculation. Imputed interest is $1,761. The lease agreement matures in October 2023.
In October 2022, the Company acquired Bothof Brothers which had an existing lease to a commercial building in Escondido, California. The building is owned by a related party. Upon acquisition, the company recognized a right-of-use asset and lease liability of $33,454 and used an effective borrowing rate of 3.0% within the calculation. Imputed interest is $2,174. The lease agreement matured in December 2024.
In January 2023, the Company’s Solas subsidiary entered into a one-year lease agreement to lease an office and medical suite in Coronado, California. The company recognized a right-of-use asset and lease liability of $47,211 and used an effective borrowing rate of 8%.
In March 2023, the Company acquired Dalrada Technology Ltd. which had an existing lease to a commercial building in Livingston, Scotland. Upon acquisition, the company recognized a right-of-use asset and lease liability of $540,615 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $125,761. The lease agreement matures in October 2027.
In March 2023, Genefic entered into a five-year lease agreement to lease a commercial building in San Diego, California. The Company recognized a right-of-use asset and lease liability of $844,242 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $185,976. The lease agreement matures in March 2028.
In March 2023, Dalrada Technology Spain S.L. entered into a five-year lease agreement to lease a commercial building in Bergondo, Spain. The Company recognized a right-of-use asset and lease liability of $125,780 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $28,129. The lease agreement matures in May 2028.
In July, 2023, Bothof Brothers entered into a 3-year lease agreement to lease a warehouse in Escondido, California. The Company recognized a right-of-use asset and lease liability of $342,211 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $39,366. The lease agreement matures in February 2026.
In October 2022, the Company acquired Genefic Infusion which had an existing lease to a building in Metairie, Louisiana. Upon acquisition, the company recognized a right-of-use asset and lease liability of $109,421 and $122,541, respectively, and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $8,838. The lease agreement matures in September 2025.
The following are the expected maturities of lease liabilities for operating leases as of June 30, 2024, including the total amount of imputed interested related:
Schedule of minimum lease payments
Fiscal Year Ended June 30,
$ 1,564,119
1,375,296
1,232,901
430,722
32,627
Thereafter -
Total lease payments 4,635,665
Less: imputed interest (366,889 )
Present value of lease liability $ 4,268,776
Other information related to operating leases for the years ended June 30, 2024, and 2023, respectively, were as follows:
Schedule of lease information
June 30, 2024 June 30, 2023
Weighted average remaining lease term - years 3.1 4.0
Weighted average discount rate 6.87% 6.75%
15. Income Taxes
We file income tax returns in the United States federal jurisdiction and in various state, local, and foreign jurisdictions. In the normal course of business, we are subject to examination by taxing authorities. The Company is currently on extension and has yet to file their income tax return for the year ended June 30, 2024.
As of June 30, 2024 and 2023, the Company had federal and state net operating loss carry forwards of $14,945,830, and $37,237,922, respectively, that may be offset against future taxable income which will begin to expire in 2038 through 2041.
The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended June 30, 2024, and 2023 is as follows:
Schedule of reconciliation of income taxes
June 30,
Current:
Federal $ - $ -
State - -
Foreign - -
Total current income tax expense 5,600 -
Deferred:
Federal (4,065,132 ) (3,267,961 )
State (1,143,034 ) (907,392 )
Total deferred income tax expense (5,208,166 ) (4,175,893 )
Valuation allowance 5,208,166 4,175,893
Total provision for income taxes $ - $ -
The provision for income tax for the year ended June 30, 2024, is included in selling, general and administrative expenses.
Deferred income taxes reflect the net tax effects of: (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes; and (b) operating loss and tax credit carryforwards. We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Significant components of deferred tax assets as of June 30, 2024, and 2023 were as follows:
Schedule of deferred taxes
June 30,
Depreciation & Amortization $ 237,475 $ 93,044
Reserves and Accruals 111,487 780,876
Research & Development Credits - -
Net Operating Loss Carryforwards 14,596,868 9,185,104
Gross Deferred Tax Assets 14,945,830 10,059,024
Valuation Allowance (14,945,830 ) (10,059,024 )
Net Deferred Tax Assets $ - $ -
Reconciliation of the statutory federal income tax to the Company's effective tax:
Schedule of reconciliation of the statutory federal income tax
June 30,
Tax at Federal Statutory Rate 21.0% 21.0%
State, Net of Federal Benefit 4.9% 4.3%
Foreign Tax 0.0% 0.0%
Tax Exempt Interest Income 0.0% (0.06)%
Gain on Expiration of Accrued Tax Liability 0.0% 0.0%
Stock Based Compensation (3.8)% (4.1)%
Nondeductible Interest 0.0% (20.1)%
Change in Valuation Allowance (22.5)% (20.6)%
Provision for Taxes (1.0)% (0.4)%
The difference in the effective rate and the statutory rate is due to permanent differences, primarily deductibility of penalties and interest on accrued payroll tax liabilities and the gains related to the expiration of the statute of limitations for accrued payroll tax liabilities.
16. Subsequent Events
On July 10, 2024, the Company entered into a promissory note with 1800 Diagonal Lending, LLC for $87,975. The promissory note includes a one-time interest charge of 14%, which was applied on the issuance date, and matures on May 15, 2025. There are 4 monthly payments of $10,029 and one payment of $60,175 for a total payback of $100,291.
On July 18, 2024, the Company executed a cash advance agreement with Cali Flower Capital Inc. with a total advance of $200,00 and payback of $299,800.
On July 25, 2024, the Company executed a revenue purchase agreement with 24 Capital with a total advance of $125,000 and payback of $187,375.
On July 29, 2024, the Company executed a revenue purchase agreement with Tycoon Capital Group with a total advance of $125,000 and payback of $187,375.
On August 12, 2024, the Company entered into an Exclusive Master Distribution Agreement (the “Agreement”) with Applied Technologies of NY, Inc. (“ATI”). The Agreement establishes the sales goals of 50 commercial heat pumps and 25 residential heat pumps in the first 18 months followed by a total of 600 heat pumps (combined commercial and residential heat pumps) in the following 12-month period.
On August 15, 2024, the Company signed a lease for 5,650 square feet of manufacturing and office space in Portland, Oregon related to the deposition technology business. The base monthly lease cost is $5,254 per month and expires on April 30, 2027.
On August 19, 2024, the Company acquired Grand Entrances for the consideration of $100 in cash, including its current liabilities and assuming its lease, which includes a monthly lease cost of $10,291 and expires on April 11, 2030.
On August 23, 2024, the Company executed a revenue purchase agreement with Quick Funding with a total advance of $170,000 and payback of $254,150.
On September 20, 2024, the Company executed a revenue purchase agreement with QFS Capital, LLC with a total advance of up to $1,573,781 and payback of $2,359,097.
On October 11, 2024, Vince Monteparte resigned as a member of the Company’s Board of Directors.
On October 12, 2024, Assurance Dimensions resigned as the Company’s auditor.
On October 15, 2024, Heather McMahon resigned as member of the Company’s Board of Directors.
On October 18, 2024, the Company engaged CM3 Advisory as its new auditor for the fiscal year ended June 30, 2024.
On October 23, 2024, the Company nominated Roger Campos as a member of the Company’s Board of Directors.

---

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
On February 14, 2024, Macias Gini & O’Connell, LLP (“MGO”), the auditor for Dalrada for the year ended June 30, 2023, ceased performing any audit or review services for the Company. Dalrada and MGO did not have any disagreements as of the date services ceased. On March 7, 2024, Dalrada engaged Assurance Dimensions for audit and review services for the year ended June 30, 2024. On October 12, 2024, Assurance Dimensions ceased performing any audit or review services for the Company. Dalrada and Assurance Dimensions did not have any disagreements as of the date services ceased. On October 18, 2024, Dalrada engaged CM3 Advisory for audit and review services for the year ended June 30, 2024.

---

ITEM 9A. CONTROLS AND PROCEDURES
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures are designed to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As required by Rule 13a-15(b) and Rule 15d-15(b) under the Exchange Act, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated, as of December 31, 2022, the effectiveness of our disclosure controls and procedures as defined in Exchange Act Rule 13a-15(c) and Rule 15d-15(e).
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such an evaluation, the Company’s Chief Executive Officer and Chief Financial Officer, have concluded that certain internal controls over financial reporting were not effective as of June 30, 2024 due to the material weaknesses described in further detail below.
Previously Reported Material Weaknesses in Internal Control over Financial Reporting
As previously disclosed in our Annual Report on Form 10-K for the year ended June 30, 2023, we identified material weaknesses in the Company’s control environment.
To address our material weaknesses, we developed a remediation plan which included the implementation and enhancement of various policies, procedures, and controls. In executing our remediation plan, during Fiscal 2024, the Company hired accounting experts to address technical accounting transactions, purchase price allocations and other accounting activity. We also implemented a strict travel and reimbursement policy and enhanced our Board of Directors and Audit Committee for better oversight of our financial reporting processes.
Material Weaknesses in Internal Control over Financial Reporting
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis. As of June 30, 2024, we continue to have material weaknesses in the Company’s control environment. Regarding the overall financial reporting structure of the Company, there is not currently a comprehensive and formalized financial reporting policies and procedures manual in place. The following sets forth internal control weakness identified:
- preparing adequate and complete schedules across the various consolidated entities including roll forwards, revenue recognition, and allowance estimates
Management’s remediation plan will focus on standardizing our reconciliation process including roll forwards and revenue recognition procedures. We look to enhance the continued improvement of our policies, procedures, and internal controls over our control environment and risk assessment.
No Attestation Report by Independent Registered Accountant
The effectiveness of our internal control over financial reporting as of June 30, 2024, has not been audited by our independent registered public accounting firm by virtue of our exemption from such requirement as a smaller reporting company.
Changes in Internal Control Over Financial Reporting
There have been no changes in internal control over financial reporting except as noted above.

---

ITEM 9B. OTHER INFORMATION
Item 9B. Other Information.
During the year ended June 30, 2024, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
PART III

---

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Item 10. Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the Exchange Act
Directors, Executive Officers, and Key Employees
The following table sets forth certain information regarding our directors, executive officers and key employees as of June 30, 2024 and as of the date of the filing of this report:
Name and Address
Age
Position(s) Held
Brian Bonar
CEO and Director
Kyle McCollum
CFO
Pauline Gourdie
Director
Brian Kendrick
Director
Anthony Zolezzi
Director
Amy Scannell
Director
Roger Campos 1
Director
Heather McMahon 2
Director
Vincent Monteparte 3
Director
1 Mr. Campos commenced service as a director as of October 23, 2024.
2 Ms. McMahon resigned as a director as of October 15, 2024.
3 Mr. Monteparte resigned as a director as of October 11, 2024.
Background of Directors and Executive Officers
Brian Bonar, CEO and Director has over 16 years with Dalrada. Prior to joining Dalrada, Mr. Bonar worked for more than eighteen years with IBM in the US, Asia, and Europe. He has formerly worked at QMS, and Rastek Corporation, The Solvis Group, and was on the Board of Directors of Allegiant Professional and Alliance National Insurance Company. Mr. Bonar is also the founder of Bezier Systems.
Mr. Bonar is involved with various private entities and has been recognized by the “Cambridge Who’s Who” on several occasions as the executive of the year. In 2012, he was recognized as the CEO of the fastest growing public company in Orange County. He is the Chairman of Trucept, Inc. as well as President and Chief Executive Officer of various privately held corporations. He is also on the board of American Marine LLC and founded American Management Services (AMS) Outsourcing, a PEO-focused company.
Mr. Bonar holds the honorary title, Lord Bonar of Wilcrick, Cardiff, Wales United Kingdom. He received a BSC in Mechanical Engineering from Strathclyde University, Glasgow Scotland and an MBA and PHD in the field of International Business Development Studies from the Stafford University, England UK.
Kyle McCollum, has served as our Chief Financial Officer since May 2021. Prior to that, Mr. McCollum was with Better Choice Company, Inc. (NYSE: BTTR) for three years where Mr. McCollum acted as Corporate Secretary and SVP of Corporate Finance.
In 2018, Mr. McCollum helped form Bona Vida, Inc., a pet CBD company, where he served as Chief Financial Officer. In May 2019, Bona Vida merged into Better Choice Company, Inc., a New York Stock Exchange-listed pet health and wellness company (NYSE: BTTR), where Mr. McCollum acted as Corporate Secretary and SVP of Corporate Finance. With Better Choice Company, he assisted in the merger of TruPet, LLC, as well as the acquisition of Halo Purely for Pets. Mr. McCollum also guided Better Choice Company in the filing of several of its 10-Q’s and its 2019 audited 10-K.
From March 2014 to July 2018, Mr. McCollum was Chief Financial Officer of Das & Co., a New York-based family office. At Das & Co., he managed all accounting, tax, audit, portfolio valuation, asset management, financial/investment reporting, and operations for Landmark Banyan Real Estate Fund, a $200 million India Real Estate Fund comprised of over 10 developments. Mr. McCollum was also Chief Operating Officer of all Das & Co.’s holding and operating subsidiaries, including Apex Resources, its mining company in Tanzania, and LDC Developers, its real estate development company.
Mr. McCollum also served as Director of Finance at 29th Street Capital, a California-based real estate investment firm with a publicly stated asset value base of US $500 million. Prior to 29th Street Capital, Mr. McCollum was Director of Finance and Corporate Compliance at Fletcher Robbe International LLP Attorneys at Law, an international transactional and securities-based law firm with offices in Century City, New York, Hong Kong and Beijing. While at Fletcher Robbe, Mr. McCollum focused on complex finance transactions, mergers & acquisitions, securities and guided several foreign listed public companies on international cross-listing to U.S. public exchanges. Mr. McCollum earned a Bachelor of Science and Master of Accountancy degree from the University of Montana and holds a Certified Public Accounting license in Montana.
Pauline Gourdie, Director - Ms. Gourdie is currently the owner/operator of CSL Staffing (“CSL”), which she established in 2016. CSL is a boutique general staffing service, providing staffing solutions for businesses in the San Diego and greater Southern California areas. For seven years prior to that, Ms. Gourdie was the President/Owner of Gourdie Consulting Corp which provided business consulting services across Americas & Europe. Ms. Gourdie possesses over 20 years of experience managing individuals and teams and was instrumental in the implementation of fulfilment and manufacturing centers for IBM and Lenovo in the United States, United Kingdom, Eastern Europe, and China.
Ms. Gourdie holds a Bachelor of Science degree in Industrial and Labor Relations from Cornell University and brings to Dalrada an extensive knowledge of supply chain management, customer account and relationship management, and recruitment and development. Ms. Gourdie was appointed to the Dalrada board on July 29, 2019 and does not receive compensation in her role as a director.
Brian Kendrick, Director - Mr. Kendrick has been the Managing Director of Allegro Jet Capital Management, LLC since 2014. Mr. Kendrick has over 30 years of business experience starting with a short stint with Burroughs as a computer programmer. Mr. Kendrick developed one of the industry's first systems for tracking owners of aircraft throughout the world and managed all aspects from the inspection and purchase of aircraft to delivery. Mr. Kendrick was appointed to the Dalrada board on July 29, 2019.
Anthony Zolezzi, Director - Mr. Zolezzi has been the CEO of Diomics Inc. since August 2019 and is on the Board of Directors of TwinLab and Wild Oats Organic Marketplace. Previously, in 2018, Mr. Zolezzi was named the CEO of Twinlab Consolidated Holdings, Inc., and appointed to Twinlab’s Board of Directors in May 2018. Mr. Zolezzi, for the last six years, is also an operating partner at Pegasus Capital Advisors, a private asset management company focused on the wellness sectors. As a serial entrepreneur, Mr. Zolezzi has dedicated his career to the well-being of both people and the planet, co-founding businesses that provide potential solutions to both health concerns and key environmental issues as well as focusing on ways that biotech breakthroughs can enhance consumer health and wellness. Zolezzi has authored and co-authored six books.
Mr. Zolezzi is a graduate of Loyola Marymount University, earned an MBA at San Diego State University and completed the Executive Development Program at the Kellogg School of Management at Northwestern University. Mr. Zolezzi is a former board member of Vitamin Angels, a non-profit focused on providing nutritional support in impoverished countries. He also co-founded and is a former board member of the Organic Center for Education and Promotion, and a former member of the Organic Alliance Board of Directors. Mr. Zolezzi also serves as an advisory board member with the Menus of Change program, a joint venture between The Culinary Institute of America and Harvard T.H.Chan School of Public Health, and the Keurig Corporation. Mr. Zolezzi was appointed to the Dalrada board in February 2021.
Amy Scannell is currently General Counsel of Tipp Investments, LLC, in Escondido California since June 2019. Tipp Investments, LLC is a company with broad investment interests including commercial real estate, agriculture, and aviation. Scannell was admitted to the California bar in 2019 and the Massachusetts bar in 2015. Prior to Tipp Investments, Scannell worked as an associate attorney for Baskin & Associates, LLC, a family law litigation firm in Boston, Massachusetts. Scannell received her Juris Doctorate from Suffolk University Law School in Boston Massachusetts and Bachelor of Arts from Westfield State University in Westfield, Massachusetts.
Roger Campos is the Founder and Chairman/CEO of the Minority Business RoundTable (MBRT), established in 2002 as the first national organization for CEOs of the nation’s Asian American, Hispanic American, African American, and Native American-owned businesses. MBRT provides a national forum for CEOs of large and small, minority, veteran, HUBZone and women-owned businesses to address public policy issues; and serves as a unique resource on business issues including federal procurement, contracting, access to capital and coaching CEO’s on how to do business with large corporations, federal and state governments. Appointed by Maryland Governor Larry Hogan, during his first term, Mr. Campos served in the Cabinet as Maryland’s first Business Ombudsman responsible for investigating and resolving complaints, issues or problems between businesses, economic development organizations, communities, and federal, state, and local agencies; and overseeing and administering Maryland’s first customer service standards. During the Governor’s second term, Mr. Campos was appointed as Assistant Secretary for Project C.O.R.E (Creating Opportunities for Renewal & Enterprise) and small business development, an economic and revitalization initiative in Baltimore City to expand business and community growth, provide new green space, affordable housing, mixed- use development, encourage investment through attractive financing, generate jobs and strengthen the partnership between Baltimore and the State of Maryland. Prior to founding MBRT, Mr. Campos was Vice President of Government Relations for the Hispanic Association of Colleges and Universities where he served as chief executive managing Washington, D.C. operations including overseeing the nationally recognized internship program that has educated more than 12,000 interns from over 500 colleges and universities. He was also Co-Founder of U.S. Hispanic Youth Entrepreneurship & Education, a nonprofit that provided students with leadership skills and college stipends. He has a distinguished public service career having served four years in the White House, Executive Office of the President, Office of Management and Budget setting up Presidential Commissions, Councils and reorganizations of federal programs; Special Assistant to the Secretary of Energy; Served as Special Consultant to the Administrator, Small Business Administration where he drafted the standard operating procedures for the U.S. federal government’s 8(a) minority business program; and served in the Office of the General Counsel, U.S. Department of Agriculture. He has also served on several Cabinet National Advisory Boards and is widely recognized as a national business leader on small business, supplier diversity, access to contracts and capital with federal, state, and local governments. Mr. Campos holds a Juris Doctorate degree from California Western School of Law in San Diego, CA and a Bachelor of Arts degree in social sciences from the University of California at Santa Barbara.
Heather McMahon is one of the nation’s top experts on counterintelligence, cybersecurity, supply chain risk management, and critical technology protection for the defense and intelligence communities. She is currently a Professor of Practice at the at the University of Maryland’s Applied Research Laboratory for Intelligence and Security (ARLIS). At ARLIS, she leads research that integrates social and behavioral sciences, computing, and artificial intelligence to advance applied research and development of capabilities in areas of critical need for the Department of Defense and the intelligence community (IC). Heather formerly served as the ARLIS Deputy Executive Direct
Previously, Heather served in the White House as Senior Director to the President’s Intelligence Advisory Board (PIAB) where she advised the Executive Office of the President and National Security Council on national security, counterintelligence, risk management, industrial security, and insider threat matters. In 2023, she was recognized with the Presidential Rank Order Award for her service there.
Prior to the White House, Heather served as a senior defense intelligence executive for the Undersecretary of Defense for Intelligence (USDI) and the Department of the Army’s Intelligence Staff where she devised, implemented, and led programs to protect DoD technology, information, personnel, facilities, and critical infrastructure from internal and external threats. Heather also served as a business development executive at a cybersecurity company.
Heather is a seasoned U.S. Army combat veteran and highly skilled human intelligence and counterintelligence officer with nearly three decades of global operational experience. This includes extensive tours in Afghanistan, Iraq, Bosnia, Europe, and Asia, serving the Army at every echelon between platoon and corps as well as in the IC’s strategic enterprise. For her exemplary service, she received the Legion of Merit, Bronze Star Medal, Meritorious Service Medal (3), DoD Counterintelligence Award for Best Counterintelligence Operations Team (2006; Iraq), and Defense Medal for Exceptional Civilian Service (2021), among other awards.
Today, Heather applies her experience and expertise to corporations on how to manage risk and defend against state-sponsored cyberattacks, insider threats, and intellectual property theft. She currently serves as a member of the Grant Committee for the Gula Tech Foundation, a civic effort focused on closing the cyber skills gap in America. She was also a national security fellow at the Foundation for Defense of Democracies and serves as a volunteer Senior Advisor to Maker Mask, a nonprofit technology-based initiative to support effective community responses to the COVID-19 crisis.
Heather is a graduate of the United States Military Academy at West Point along with numerous advanced Intelligence Community and military schools including the Army’s Jumpmaster School and Airborne School. As a writer, she has appeared in the Washington Post and the US Army War College War Room (co-author with Michael Schellhammer).
Vincent Monteparte is Principal and Venture Partner in the venture capital and investment banking industry, having managed transactions and investments ranging from $40M to $500M. His leadership transformed uniquely positioned mid-market organizations in the enterprise software sector to upwards of $2 billion in enterprise valuations. A diverse background in technology, aerospace, transportation, logistics, real estate and healthcare has led Mr. Monteparte to roles as Venture Partner at Sway Ventures, a US-based venture capital firm investing in early to mid-stage technology companies and Principal at Global Capital Markets, an investment banking firm focusing on mid-market transactions for technology, manufacturing, distribution, service and retail companies.
Mr. Monteparte began his career as an entrepreneur and founded various companies, most recently Miro Technologies. At Miro, he led the development of a SaaS solution to modernize maintenance, repair, overhaul, and supply chain operations for complex assets. The business was sold to Boeing for 14x return on invested capital with an IRR of 48%. Additionally, Mr. Monteparte has since held various senior level executive roles leading teams and positioning multinational corporations to growth.
Mr. Monteparte holds a series 63 and 79 license and Board Advisory positions for BlueSky eLearn, a leading learning management software platform and Measurabl, a global ESG SaaS Software company. He received a B.A. in Aeronautical Engineering from Embry-Riddle Aeronautical University and an MBA from the Pepperdine University Graziadio School of Business, where he earned the Most Distinguished Alumni Award. In his spare time, Mr. Monteparte co-chairs the Business & Entrepreneurship Committee at Pepperdine, where he acts as a mentor to young entrepreneurs and executives in career and portfolios.
Term of Office of Directors
Our directors are appointed for a one-year term to hold office until the next annual general meeting of our stockholders or until removed from office in accordance with our bylaws. Our officers are appointed by our Board of Directors and hold office until the officer dies or resigns or the Board elects a successor or removes the officer.
Key Employees
David Pickett, is currently Executive Vice President of Sales and Marketing. Mr. Pickett’s professional background includes 25 years’ experience in executive relationship development and business growth with several companies including Celestica Inc. and Axxion Inc. Mr. Pickett has worked with the largest OEM and Fortune 500 companies in the world. Mr. Pickett’s vast knowledge base of engineering and manufacturing operational and supply chain requirements has proven to be a strategic asset for accelerating the growth of Dalrada Precision’s global manufacturing and clean energy initiatives through its portfolio company Likido.
Family Relationships
Pauline Gourdie is the daughter of Brian Bonar.
Audit Committee Financial Expert
No determination has been made as to whether any member of the audit committee qualified as an audit committee financial expert as defined in Item 401 of Regulation S-K.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and executive officers, and persons who beneficially own more than 10% of a registered class of our equity securities, to file reports of beneficial ownership and changes in the beneficial ownership of our securities with the SEC of Forms 3 (Initial Statement of Beneficial Ownership), 4 (Statement of Changes of Beneficial Ownership of Securities) and 5 (Annual Statement of Beneficial Ownership of Securities). Directors, executive officers and beneficial owners of more than 10% of our Common Stock are required by SEC regulations to furnish us with copies of all Section 16(a) forms that they file. The required filings will be made.
Code of Ethics
We have adopted an informal Code of Ethics that applies to our officers and directors, which we feel is sufficient at this time.

---

ITEM 11. EXECUTIVE COMPENSATION
Item 11. Executive and Director Compensation
SUMMARY COMPENSATION TABLE
Name and Principal
Stock Option All Other
Position Year Salary Bonus Awards Awards Compensation Total
Brian Bonar, CEO 432,300 - 158,928 - - 591,228
Kyle McCollum, CFO 375,000 100,000 - - - 475,000
Pauline Gourdie - - 158,928 - - 158,928
Brian Kendrick - - 158,928 - - 158,928
Anthony Zolezzi 43,824 - 158,928 - - 202,752
Amy Scannell -
158,928 - - 158,928
Vincent Monteparte - - 158,928 - - 158,928
Heather McMahon - - - - - -
Total
851,124 100,000 953,568 - - 1,904,692
Name and Principal
Stock Option All Other
Position Year Salary Bonus Awards Awards Compensation Total
Brian Bonar, CEO 393,000 - - - - 393,000
Brian McGoff, COO 350,719 - 479,623 - - 830,342
Kyle McCollum, CFO 375,062 75,000 248,916 - - 698,978
Pauline Gourdie - - - - - -
Brian Kendrick - - - - - -
Anthony Zolezzi 23,415 - - - - 23,415
Amy Scannell -
- - - -
Vincent Monteparte - - - - - -
Anuradha Biswas - - 90,345 - - 90,345
Total
1,142,196 75,000 818,844 - - 2,036,080
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE
OPTION AWARDS
STOCK AWARDS
Equity
Equity Incentive
Incentive Plan
Plan Awards:
Awards: Market
Number or Payout
of Value of
Market Unearned Unearned
Number of Number of
Number Value of Shares, Shares,
Securities Securities
of Shares Shares or Units or Units or
Underlying Underlying
or Units Units Other Other
Unexercised Unexercised
of Stock of Stock Rights Rights
Options and Options and Option
That Have That Have That That
Warrants Warrants Exercise Option Not Not Have Not Have Not
Name and Principal
(#) (#) Price Expiration Vested Vested Vested Vested
Position(s)
(Exercisable) (Unexercisable) ($) Date (#) ($) (#) ($)
Brian Bonar, CEO
500,000 - 0.45 7/7/2030 - - - -
Brian Bonar, CEO
515,068 484,932 0.10 6/19/2033 - - - -
Kyle McCollum, CFO
1,000,000 - 0.47 5/10/2031 - - - -
Kyle McCollum, CFO
500,000 - 0.45 7/7/2030 - - - -
Kyle McCollum, CFO
1,413,699 1,586,301 0.16 1/28/2033 - - - -
Pauline Gourdie
500,000 - 0.45 7/7/2030 - - - -
Pauline Gourdie
515,068 484,932 0.10 6/19/2033 - - - -
Brian Kendrick
500,000 - 0.45 7/7/2030 - - - -
Brian Kendrick
515,068 484,932 0.10 6/19/2033 - - - -
Anthony Zolezzi
500,000 - 0.45 7/7/2030 - - - -
Anthony Zolezzi
515,068 484,932 0.10 6/19/2033 - - - -
Amy Scannell
500,000 - 0.45 2/14/2032 - - - -
Amy Scannell
515,068 484,932 0.10 6/19/2033 - - - -
Vincent Monteparte
500,000 - 0.45 2/14/2032 - - - -
Vincent Monteparte
515,068 484,932 0.10 6/19/2033 - - - -
Director Compensation
On July 9, 2020, the Board authorized the Dalrada Financial Corporation 2020 stock compensation plan to be used to compensate the company board of directors. The plan allocates the issuance of up to 3,500,000 shares. On February 25, 2021, the Company amended the plan to issue up to 4,500,000 shares and issued an aggregate of 4,500,000 common shares, or 500,000 shares to each board member (9). 3,500,000 shares of common stock were granted on July 9, 2020, at $0.08 per share and 1,000,000 shares of common stock were granted on February 25, 2021, at $0.45 per share, for a total fair value of $730,000, which is included in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
On August 16, 2021, the Company approved Amendment No.1 of the 2020 Stock Compensation Plan used to compensate the Company board of directors. The Amended plan allocates the issuance of up to 6,500,000 shares which includes an additional 2,000,000 shares valued at $0.28 per shares or $560,000.
On September 30, 2021, the Board of Directors through email correspondence, approved Amendment No. 3 of the 2020 Stock Compensation Plan used to compensate the Company board of directors. The Board Directors agree to the following changes;
1) Cancellation and return to treasury of all the commons shares issued under the previous 2020 Stock Compensation Plan and amendments totaling 6,500,000 shares of common stock.
2) Ability to issue Cashless Warrants for up to 10,000,000 shares of the Company’s Common Stock, at $.005 par value per share (“Common Stock”) at 500,000 shares per board member, key employees, or consultants with an exercise price at $0.45 per common share.
3) The vesting period for the Warrants shall be as follows:
a) Warrants issued to replace the 4,500,000 shares issued pursuant to the July 9, 2020, grant date will be fully vested;
b) Warrants issued to replace the 2,000,000 shares issued pursuant to the July 19, 2021, grant date and any later grant dates will vest over a one-year period.
On February 16, 2022, the Company issued 2,250,000 cashless warrants to new members of the Board of Directors. The cashless warrants vest over a 12-month period and hold an exercise price of $0.45 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.59 per share, or $1,338,644, which was calculated using the Black-Scholes model.
On June 20, 2023, the Company issued 1,000,000 cashless warrants to new members of the Board of Directors. The cashless warrants vest over a 24-month period and hold an exercise price of $0.10 per share. The cashless warrants expire in ten years after issuance. The fair value of the cashless warrants granted was $0.18 per share, or $953,565 which was calculated using the Black-Scholes model.
Employment Agreements
On July 1, 2019, the Company entered into an employment agreement with the Chief Executive Officer of the Company. Pursuant to the agreement, the Company will compensate the Chief Executive Officer a base salary of $393,000 per annum, annual increases of 10% and a quarterly bonus based on whether the Company achieves a net profit. He will be issued common stock of the Company sufficient to provide a 10% ownership position only upon a reverse split, which shares are to be maintained for a period of two years. In addition to all other benefits and compensation, he shall be eligible for a quarterly bonus of $47,000 based on if the Company achieves a net profit for that quarter. The Chief Executive Officers base salary has been deferred and accrued by the Company.
Report on Repricing of Options
None.

---

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The following table provides certain information regarding the ownership of our common stock, as of June 30, 2024, and as of the date of the filing of this Annual Report on Form 10-K by:
· each of our executive officers;
· each director;
· each person known to us to own more than 5% of our outstanding common stock; and
· all our executive officers and directors act as a group.
As of January 8, 2025, we had a total of 120,157,113 shares of common stock issued and outstanding held by a total of 605 shareholders of record. Except as indicated in footnotes to this table, the persons named in this table have sole voting and investment power with respect to all shares of common stock indicated below.
Name and Address of Beneficial Owner Title of Class Amount and
Nature of Beneficial
Ownership
(1) (#)
Percent of Class
(2) (%)
Brian Bonar, Chief Executive Officer and Director3 Common Shares 25,810,046 20.99
Kyle McCollum, Chief Financial Officer4 Common Shares 3,445,205 3.42
Pauline Gourdie, Director5 Common Shares 1,280,822 1.30
Brian Kendrick, Director5 Common Shares 1,280,822 1.30
Anthony Zolezzi, Director5 Common Shares 1,280,822 1.30
Amy Scannell, Director5 Common Shares 1,280,822 1.30
Roger Campos, Director Common Shares
All officers and Directors as a group (seven persons) Common Shares 34,378,539 27.44
1 Unless otherwise noted, each person or group identified possesses sole voting and investment power with respect to such shares.
2 Applicable percentage of ownership is based on 97,175443 shares of Common Stock outstanding as of January 10, 2025, plus, for each stockholder, all shares that such stockholder could acquire within 60 days of January 10, 2025, upon the exercise of existing warrants or conversion of existing convertible securities.
3 Includes 6,258,198 common shares; 18,271,026 common shares that can be purchased within 60 days of January 10, 2025, upon the conversion of 4,537 Series I Preferred Shares, 247 Series H Preferred Shares, and 1,529 Series I Preferred Shares; and 1,280,822 shares that can be purchased within 60 days of January 10, 2025, upon the exercise of 1,280,822 warrants.
4 Includes 3,445,205 shares that can be purchased within 60 days of January 10, 2025, upon the exercise of 3,445,205 warrants.
5 Includes 1,280,222 shares that can be purchased within 60 days of January 10, 2025, upon the exercise of 1,280,222 warrants.
The address for each of the persons listed in the chart is 600 La Terraza Blvd., Escondido, California 92025.

---

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Item 13. Certain Relationships, Related Transactions and Director Independence
Notes Payable - Related Parties
June 30, 2024
Outstanding Accrued
Principal Interest
Related entity 1 $ - $ -
Related entity 2 52,887 -
Related entity 3 - -
Related entity 4 1,070 -
Related entity 5 - -
Related entity 6 - -
$ 53,957 $ -
June 30, 2023
Outstanding Accrued
Principal Interest
Related entity 1 $ 1,380,672 $ 3,038
Related entity 2 126,864 -
Related entity 3 105,000 -
Related entity 4 50,074 -
Related entity 5 - -
Related entity 6 237,473 11,144
$ 1,900,083 $ 14,182
All notes dated December 31, 2022, and prior are unsecured, bear interest at 3% per annum, and are due 360 days from the date of issuance, ranging from June 25, 2020, to December 30, 2022. All notes dated after December 31, 2022, are unsecured, bear interest at 8% per annum, and are due 1095 days from the date of issuance.
Convertible Note Payable - Related Parties
On June 30, 2019, the Company issued a convertible note for $1,875,000 to the Chief Executive Officer of the Company for compensation. Under the terms of the note, the amount due is unsecured, bears interest at 3% per annum, and was due 360 days from the date of issuance. On June 30, 2019, the Company issued a note agreement which included a conversion feature of the outstanding balance at $0.034 per share. As the conversion price was equal to the fair value of the common shares on the date of the agreement, there was no beneficial conversion feature. As of June 30, 2024, the principal balance was $0 and the accrued interest was $0.
Related Party Transactions
On July 1, 2019, the Company formalized an employment agreement with its Chief Executive Officer, which entitles him to compensation of three hundred and ninety-three thousand dollars ($393,000) per year. Annual increases will be up to 10% based on performance criteria to be determined at a later date. He will be issued common stock of the Company sufficient to provide a 10% ownership position post reverse split, which shares be maintained for a period of two years. In addition to all other benefits and compensation, he shall be eligible for a quarterly bonus of $47,000 based on if the Company achieves a net profit for that quarter. As of June 30, 2024, and 2023, the Company had $0 and $0, accrued within accounts payable and accrued liabilities - related parties, respectively.
The following is a summary of revenues recorded by the Company’s to related parties with common ownership:
Year Ended
June 30,
Dalrada Health $ - $ 76,912
Dalrada Energy Services 5,207 45,968
Ignite
Prakat 15,000 25,000
Bothof Brothers 1,697,485 2,134,470
$ 1,717,832 $ 2,282,746
Director Independence
The OTC Markets Group Inc. does not have a requirement that a majority of our Board of Directors be independent. However, with respect to the definition of independence utilized by NASDAQ, our officers, other than Mr. Bonar, would be deemed to be independent.
Our Audit Committee is comprised of our officers and directors. NASDAQ requires at least three members on the Audit Committee, each of whom must be independent. NASDAQ also requires that, if the Chief Executive Officer’s compensation is determined by its Compensation Committee, the Compensation Committee must be comprised solely of independent directors. The Company currently does not meet either of these requirements.
The NASDAQ rules have both objective tests and a subjective test for determining who is an “independent director.” The objective tests state, for example, that a director is not considered independent if he or she is an employee of the Company or is a partner, executive officer or controlling stockholder of an entity to which the Company made, or from which the Company received, payments in the current or any of the past three fiscal years that exceed the greater of $200,000 or 5% of the recipient’s consolidated gross revenue for that year or a family member serves in the current fiscal year or has served at any time during the last three fiscal years as an executive officer of the Company. The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

---

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
Item 14. Principal Accountant Fees and Services
The Company incurred $236,424 in audit feeds for the year ended June 30, 2023. Fees for the year ended June 30, 2024 are to be provided upon issuance of the audited Form 10-K.
"Audit Fees" consisted of fees billed for services rendered for the audit of the Company’s annual financial statements and “Audit-Related Fees are for review of the financial statements included in the Company’s quarterly reports on Form 10-Q.

---

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
Item 15. Exhibits
The financial statement schedules are omitted because they are inapplicable, or the requested information is shown in our financial statements or related notes thereto.
Exhibits
Exhibit
Number
Exhibit
Description
31.1
Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH
Inline XBRL Taxonomy Extension Schema Document
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
Cover Page Interactive Data File (formatted in inline XBRL and included in exhibit 101).